The Science
The Research Behind Fascia, Chronic Pain, Stiffness, and Lissom™
Fascial dysfunction, fascia dehydrating, densifying and compressing the nerves inside it, is emerging in the peer-reviewed literature as a driver of chronic pain and stiffness. This page is the research behind that. Part A collects what published studies have found about fascia: what it is, how it senses pain, how it densifies, how it is measured, and what has been found in specific conditions. Part B lists the published research on each of the nine ingredients in Lissom™. Every study carries a label saying what kind of evidence it is, a plain summary of what it found, and a link to PubMed or the journal.
Last reviewed 29 September 2026. Every link goes to PubMed or the journal.
How to read this page
Each study has an evidence label. The label tells you how much weight the study can carry. A meta-analysis or randomised controlled trial can show whether something works in people. An imaging or anatomical study can show that a tissue is different in people with a condition. A lab, animal or review paper can explain a mechanism but cannot show an effect in patients. We use all of these, because a research picture is built from all of them, and we label them so you can tell which is which.
Where a study was sponsored by the company that makes the ingredient tested, the note says so, as is standard for ingredient trials. Where two good studies differ, both are listed.
Pooled statistical analysis of several trials. Highest level of evidence when the trials are good.
A structured search and summary of all studies on a question, without pooling numbers.
Participants randomly assigned to treatment or control. The standard for testing whether something works.
A human trial without randomisation, or an open-label trial without placebo.
An experiment in human volunteers, such as injecting fascia to test its sensitivity, rather than a treatment trial.
Ultrasound, elastography or MRI measurements of fascia in patients compared with controls.
Human tissue studied under the microscope or in dissection.
Cell culture, animal or biochemical work. Explains mechanism; does not show an effect in people.
A few patients treated and described, with no control group.
A narrative summary or hypothesis paper written by experts. Useful for context; not primary evidence.
A paper proposing definitions or terminology.
Part A
Fascia
Fascia is the connective tissue that fills the space between everything else in the body. It is one continuous layer wrapping every muscle, nerve, joint and organ. Until recently it was treated as packaging. The research below, most of it from the last five to ten years, is why that view has changed.
What fascia is13 studies
Healthy fascia is soft, supple and mostly water. That water is held in place by hyaluronic acid, made by cells inside the fascia itself, and by a framework of collagen. As long as the fascia gets its supply of water and nutrients, its layers stay hydrated and move freely over the muscles and nerves they wrap. The studies here are the anatomy: what fascia is made of, the cells that keep it hydrated, and how much hyaluronic acid different parts of the body carry.
2017Definition paperDefining the fascial systemJournal of Bodywork and Movement Therapies. Adstrum S et al.
Who and what was studiedConsensus paper from the Fascia Research Society's Fascia Nomenclature Committee.
What it foundReports the committee's proposed definition of the fascial system as a body-wide soft connective tissue network, and sets out why the term needed a shared definition across disciplines.
Study notesConsensus statement, not a data study.
2025Definition paperTowards a comprehensive definition of the human fascial systemJournal of Anatomy. Stecco C, Pratt RL, Nemetz LD, Schleip R, Stecco A, Theise ND.
Who and what was studiedProposal from six fascia researchers integrating histological, mechanical and clinical data.
What it foundProposes that fasciae form an anatomical system: a layered, body-wide network of connective tissue that allows tensional loading and shearing mobility along its interfaces. Describes two basic layer types, one collagenous and stiff, the other rich in hyaluronic acid and viscous, allowing free flow of fluid.
Study notesProposal from a group of leading fascia researchers.
2011Anatomical studyHyaluronan within fascia in the etiology of myofascial painSurgical and Radiologic Anatomy. Stecco C et al.
Who and what was studiedDeep fascia and underlying muscle from neck, abdomen and thigh of three fresh cadavers, plus ultrasound of 22 volunteers.
What it foundFound a layer of hyaluronan between fascia and muscle and within the loose connective tissue that divides the fibrous sublayers of deep fascia, along with fibroblast-like cells that appear specialised for producing it (later named fasciacytes). Mean deep fascia thickness on ultrasound: 1.88 mm fascia lata, 1.68 mm rectus sheath, 1.73 mm sternocleidomastoid fascia.
Study notesSmall cadaveric sample; mechanism proposed, not tested.
2018Anatomical studyThe fasciacytes: a new cell devoted to movement between fascial layers regulationClinical Anatomy. Stecco C et al.
Who and what was studiedHuman fascia samples; Alcian blue staining, hyaluronan-binding-protein immunohistochemistry, electron microscopy and RT-PCR for HAS2.
What it foundIdentifies a fibroblast-like cell type (vimentin-positive, CD68-negative, expressing HAS2 mRNA) located where fascia meets muscle and between fascial sublayers, which produces the hyaluronan-rich matrix. The authors name these cells fasciacytes and note that hyaluronan is essential for movement between fascial layers.
Study notesSingle research group; sample size not stated in abstract.
2018Anatomical studyQuantification of hyaluronan in human fasciae: variations with function and anatomical siteJournal of Anatomy. Fede C et al.
Who and what was studiedHuman fascial samples from several anatomical sites.
What it foundFirst direct measurement of hyaluronan content in human fascia. Amount varies by site and by how much the fascia needs to slide: about 35 µg/g in fascia lata and 29 µg/g in the rectus sheath, about 6 µg/g in fascia adherent to muscle (trapezius, deltoid), and about 90 µg/g in the ankle retinacula where movement is greatest. No significant differences by age or sex except in the plantar fascia.
Study notesCross-sectional tissue analysis.
2016Anatomical studyHormone receptor expression in human fascial tissueEuropean Journal of Histochemistry. Fede C et al.
Who and what was studiedFascia from 8 women aged 42–70 (pre- and post-menopausal) collected during orthopaedic surgery, plus cultured fascial fibroblasts.
What it foundEstrogen receptor alpha and relaxin receptor 1 are expressed in fibroblasts across all fascial sites examined, and to a lesser degree in post-menopausal women. Relaxin receptor was also present on blood vessels and nerves. Proposed as a link between hormonal factors and myofascial pain.
Study notesTissue from eight women.
2019Animal or lab studySensitivity of the fasciae to sex hormone levels: modulation of collagen-I, collagen-III and fibrillin productionPLOS ONE. Fede C et al.
Who and what was studiedFibroblasts isolated from human fascia lata, treated in vitro with β-estradiol and relaxin-1 at levels matching menstrual phases, menopause and pregnancy.
What it foundFascial cells changed their extracellular matrix output according to hormone levels. With β-estradiol, collagen-I positivity fell from 6% (follicular) to 1.9% (periovulatory); adding relaxin-1 reduced matrix production further. The authors describe this as a first step toward understanding how hormonal changes can dysregulate matrix production in fascia.
Study notesCell culture study.
2024ReviewFascia as a regulatory system in health and diseaseFrontiers in Neurology. Slater AM et al.
Who and what was studiedNarrative mini-review.
What it foundDescribes the fascial system as highly innervated and rich in blood vessels, lymphatics, and hormone and neurotransmitter receptors, and reviews its contiguous relationship with the nervous system. Proposes fascial dysregulation as a factor in hypermobility syndromes, autonomic dysregulation, mast cell activation and acquired connective tissue disorders.
Study notesHypothesis-generating review.
2021Anatomical studyAn anatomical comparison of the fasciae of the thigh: a macroscopic, microscopic and ultrasound imaging studyJournal of Anatomy. Pirri C et al.
Who and what was studiedFascial layers from three fresh cadavers compared with ultrasound of 20 healthy volunteers.
What it foundMaps the layered structure of thigh fascia (superficial adipose layer, superficial fascia, deep adipose layer, aponeurotic and epimysial deep fascia) and reports thickness by region, for example deep fascia 556.8 ± 176.2 µm anteriorly and 1112 ± 237.9 µm laterally on histology. Establishes reference values for reading fascia on ultrasound.
Study notesHealthy volunteers only.
2021ReviewHyaluronan and the fascial frontierInternational Journal of Molecular Sciences. Pratt RL.
Who and what was studiedNarrative review of hyaluronan biology in fascia.
What it foundReviews hyaluronan as the most abundant polysaccharide of connective tissue matrix, its responsiveness to chemical, mechanical and hormonal change, and its role in movement between fascial layers, from fasciacytes through to chronic pain.
Study notesReview; mechanism partly inferred from non-fascial tissues.
2025Systematic reviewThe future of fascia: a scoping review on emerging research trends and recommended sample sizes and effect sizes in fascia studiesInternational Journal of Molecular Sciences. Zieliński G.
Who and what was studiedScoping review; 31 meta-analyses used to calculate effect-size and sample-size benchmarks.
What it foundFinds that future fascia research is likely to focus on its role in movement organisation and chronic pain, particularly in older adults, and that modern imaging and manual or movement therapies may change how fascial dysfunction is diagnosed and treated. Proposes effect-size thresholds and a minimum sample size for fascia studies.
Study notesMethodological paper.
2023Anatomical studyDetection of mast cells in human superficial fasciaInternational Journal of Molecular Sciences. Fede C et al.
Who and what was studiedSuperficial fascia from the abdominal wall of three adult volunteers; toluidine blue and safranin-O staining and electron microscopy.
What it foundMast cells, the immune cells that release histamine and inflammatory mediators, are distributed through the superficial fascia among the collagen bundles, near the vessels and close to the nerves, at about 20 per mm². The fascia contains its own inflammatory cells, which the authors say is fundamental to understanding fascial dysfunction.
Study notesSmall anatomical sample.
2025Systematic reviewHistology of the fascial planes: a systematic review of the microstructural foundations of regional anesthesiaJournal of Anesthesia, Analgesia and Critical Care. De Cassai A et al.
Who and what was studiedSystematic review of 17 histological studies of human fascial planes in the thoracic, abdominal, lumbar and lower limb regions.
What it foundStates that fascia, once viewed as a passive structural tissue, is now recognised as a biologically active interface integral to stability, force transmission, proprioception and nociception, and confirms that fasciae share a multi-layered organisation of dense and loose connective tissue layers, with the innervation and vascularisation that make them relevant to pain.
Study notesRegistered systematic review.
Fascia as a sensory tissue15 studies
Fascia is not just wrapping. It is wired. Studies in animals and humans show dense networks of nerve endings inside fascia, many of them the kind that register pain, and their number goes up when the tissue is irritated. In experiments with healthy volunteers, stimulating the fascia produced more pain, for longer and over a wider area, than stimulating the muscle beneath it. This is why compressed fascia can produce pain that imaging of muscle, bone and joints never explains.
2011Anatomical studySensory innervation of the thoracolumbar fascia in rats and humansNeuroscience. Tesarz J, Hoheisel U, Wiedenhofer B, Mense S.
Who and what was studiedQuantitative immunohistochemistry of CGRP- and substance P-containing nerve endings in rat thoracolumbar fascia, with a preliminary evaluation in human specimens.
What it foundThe thoracolumbar fascia is densely innervated, with marked differences between layers. Substance P-positive free nerve endings, which are assumed to be nociceptive, were found only in the outer layer and adjoining subcutaneous tissue. The authors conclude the fascia may play an important role in low back pain.
Study notesQuantified in rat tissue, confirmed in human specimens.
2019Anatomical studyInnervation of the thoracolumbar fasciaEuropean Journal of Translational Myology. Mense S.
Who and what was studiedImmunohistochemistry of rat thoracolumbar fascia, with some human findings.
What it foundThe only receptive nerve ending found was the free nerve ending; no corpuscular receptors were present. Most fibres stained for CGRP and substance P, the latter most likely nociceptors. Comparing inflamed with intact fascia showed an increase in CGRP- and SP-positive fibres in the inflamed tissue, offered as one explanation for low back pain since lesions of the fascia are accompanied by sterile inflammation.
Study notesMainly rat tissue, with human findings included.
2011Animal or lab studyNociceptive input from the rat thoracolumbar fascia to lumbar dorsal horn neuronesEuropean Journal of Pain. Hoheisel U et al.
Who and what was studiedElectrophysiological recordings from spinal dorsal horn neurones in anaesthetised rats.
What it foundSix to fourteen percent of neurones in segments Th13–L2 received nociceptive input from the thoracolumbar fascia. After an experimentally induced inflammation of a low back muscle, the proportion of neurones responsive to fascia input rose from 4% to 15%, and neurones in a segment that normally had no fascia input began responding. The data suggest fascial nociceptive input contributes to low back pain.
Study notesAnimal study.
2021Animal or lab studyEvidence of a new hidden neural network into deep fasciaeScientific Reports. Fede C et al.
Who and what was studiedThoracolumbar (aponeurotic) and gluteal (epimysial) fascia of 7 adult mice; electron microscopy and immunohistochemistry.
What it foundFascial tissue is pervaded by a dense, rhomboid network of nerves. Innervation was significantly higher in the thoracolumbar fascia (9.01 ± 0.98% of area; 500.9 ± 43.1 branching points/mm²) than the gluteal fascia (2.78 ± 0.6%; 140.3 ± 31.6/mm²). Both contained autonomic fibres at the same density.
Study notesMouse study.
2022Systematic reviewFascial innervation: a systematic review of the literatureInternational Journal of Molecular Sciences. Suarez-Rodriguez V et al.
Who and what was studied23 histological and immunohistochemical studies (2000–2021): 10 in humans, 2 in humans and rats, the rest in rats, mice and horses.
What it foundThe thoracolumbar fascia was the most studied region. Across studies the fasciae show diverse innervation, from free nerve endings to Pacini and Ruffini corpuscles, with CGRP and substance P among the most common markers, and fasciae are increasingly considered a possible source of myofascial pain.
Study notesIncludes human and animal histology.
2020Anatomical studyFascia and soft tissues innervation in the human hip and their possible role in post-surgical painJournal of Orthopaedic Research. Fede C et al.
Who and what was studiedTen tissue types (skin, fat, superficial and deep fascia, muscle, capsule, ligaments, tendon) from 11 hip-surgery patients and 2 cadavers, stained for Schwann cells.
What it foundSkin was the most innervated tissue (0.73 ± 0.37% positive area) and tendon the least (0.07 ± 0.01%). Superficial fascia showed 0.22–0.26% positive area with networks of small fibres, while muscle had a similar percentage but carried by a few large nerves. The authors propose fascia and soft tissue innervation as a factor in persistent pain after hip surgery.
Study notesSmall sample; no pain comparison group.
2022Anatomical studyInnervation of human superficial fasciaFrontiers in Neuroanatomy. Fede C et al.
Who and what was studiedSuperficial fascia from the abdomen and thigh of surgical patients; histology and immunohistochemistry for nerve and sympathetic markers.
What it foundThe superficial fascia carries a large innervation, found around blood vessels, near adipocytes and within the connective tissue itself, as both thin (4.8 ± 2.6 µm) and larger (21.1 ± 12.2 µm) nerve bundles. About a third of the innervation was autonomic (S100/TH ratio 2.96; 33.82% autonomic).
Study notesDescriptive; sample size not stated in abstract.
2014Human experimental studySensory findings after stimulation of the thoracolumbar fascia with hypertonic saline suggest its contribution to low back painPain. Schilder A et al.
Who and what was studied12 healthy volunteers; ultrasound-guided injections of hypertonic saline into erector spinae muscle, the posterior layer of the thoracolumbar fascia, and the overlying subcutis.
What it foundInjections into the fascia produced a significantly larger pain response over time than injections into subcutis (p<0.01) or muscle (p<0.001), mainly through longer pain duration. Pain radiation and pain affect from fascia injection exceeded those from muscle and subcutis. Pain descriptors (burning, throbbing, stinging) suggested both A- and C-fibre nociceptors.
Study notesAcute experimental pain in healthy people, not chronic pathology.
2022Human experimental studyDose-dependent pain and pain radiation after chemical stimulation of the thoracolumbar fascia and multifidus muscleLife. Vogel S et al.
Who and what was studied16 healthy subjects; 50, 200 and 800 µL hypertonic saline injections into thoracolumbar fascia and multifidus muscle in a single-blinded cross-over design.
What it foundInjections into fascia produced significantly higher peak pain (+86%, p<0.001), longer pain duration (p<0.05) and larger pain areas (+65%, p<0.02) than the same injections into muscle. Higher volumes into muscle did not compensate for its lower sensitivity.
Study notesAcute experimental model; healthy volunteers.
2012Human experimental studyNGF-evoked sensitization of muscle fascia nociceptors in humansPain. Deising S et al.
Who and what was studied14 male volunteers; nerve growth factor injected under ultrasound guidance into the fascia of the lumbar erector spinae, with sensitivity tested over 21 days.
What it foundNGF produced a lasting (days 1–7) and significant reduction in pressure pain thresholds and increased exercise-evoked muscle pain and hyperalgesia to impact stimuli; pain on injection of acidic buffer remained elevated for two weeks. The authors conclude fascia nociceptors appear particularly prone to sensitisation and may contribute to acute or chronic muscle pain.
Study notesSmall experimental study in healthy men.
2021ReviewFascia mobility, proprioception, and myofascial painLife. Langevin HM.
Who and what was studiedNarrative review by the director of the NIH National Center for Complementary and Integrative Health.
What it foundNotes that fasciae, especially the deep epimysium and aponeuroses, have recently been recognised as highly innervated with small-diameter fibres that can transmit nociceptive signals, particularly in the presence of inflammation. Proposes that fascia mobility along shear planes is critical for function and may play a role in proprioception and myofascial pain.
Study notesPerspective paper from the NIH.
2019Animal or lab studyFascia is able to actively contract and may thereby influence musculoskeletal dynamicsFrontiers in Physiology. Schleip R et al.
Who and what was studiedHuman fascial specimens from 31 donors and rat fascia from 20 animals; immunohistochemistry for myofibroblasts and force measurements on isolated rat fascia.
What it foundMyofibroblast density was higher in human lumbar fascia than in fascia lata or plantar fascia. Isolated fascial tissue contracted in response to TGF-β1 and other stimulants, and myofibroblast density correlated with contractile response (r = 0.83, p<0.001). Suggests fascia can generate its own tension.
Study notesEx vivo tissue; force predictions for whole-body effects are modelled, not measured.
2015Animal or lab studyInflammation of the thoracolumbar fascia excites and sensitizes rat dorsal horn neuronsEuropean Journal of Pain. Hoheisel U, Rosner J, Mense S.
Who and what was studiedRats with the thoracolumbar fascia experimentally inflamed for 12 days versus saline controls; recordings from spinal neurons.
What it foundAfter the fascia was inflamed, spinal neurons that normally receive no input from it began responding (11.1%), the proportion responding to deep tissue rose from 10.8% to 33.3%, and many neurons acquired new receptive fields in the leg. Inflamed fascia recruits spinal circuits it normally does not reach, which the authors offer as an explanation for how pain spreads.
Study notesAnimal study.
2015Animal or lab studyInnervation changes induced by inflammation of the rat thoracolumbar fasciaNeuroscience. Hoheisel U et al.
Who and what was studiedHistology of inflamed versus intact thoracolumbar fascia in rats, quantifying nerve fibre length and free nerve endings by layer.
What it foundWhen fascia is inflamed, the density of substance P-positive, presumably pain-sensing, fibres increases significantly. Pain from fascia can come not only from nerve endings firing more, but from more pain-sensing endings growing into it.
Study notesAnimal study.
2016Animal or lab studyEvidence for the existence of nociceptors in rat thoracolumbar fasciaJournal of Bodywork and Movement Therapies. Mense S, Hoheisel U.
Who and what was studiedHistology of rat thoracolumbar fascia using markers for pain-sensing fibres (CGRP, substance P, TRPV1), with and without induced inflammation.
What it foundPain-sensing fibre density increased significantly in the inner and outer fascial layers when the fascia was inflamed, and electrically stimulating the nerve roots produced plasma leakage in the fascia, which is direct functional proof that fascia has nociceptors. The authors conclude this may explain pain from a pathologically altered fascia.
Study notesAnimal study.
Fascial densification13 studies
When fascia loses its supply of water and nutrients, the hyaluronic acid inside it clumps and the fluid between its layers thickens. The tissue densifies: it stiffens, its layers stop moving over each other, and it compresses the muscles and nerves running through it. The pain literature coined the term fascial densification in 2014 to describe exactly this change, and separated it from fibrosis, which is scarring of the collagen layers themselves. Densification is described as reversible. The studies below are the evidence for the concept, the physics behind it, and the observations that support its reversal.
2014ReviewPainful connections: densification versus fibrosis of fasciaCurrent Pain and Headache Reports. Pavan PG, Stecco A, Stern R, Stecco C.
Who and what was studiedReview of deep fascia structure and mechanics.
What it foundThe paper that separates the two terms. Densification is a change in the viscosity of the loose connective tissue within fascia, which the authors describe as easily reversible and linked to diet, exercise and overuse. Fibrosis is an alteration of the fibrous layers themselves, linked to trauma, surgery, diabetes and ageing. Both can modify the mechanical properties of deep fascia and enmesh nerve receptors.
Study notesThe review that defined the terms.
2013ReviewFascial components of the myofascial pain syndromeCurrent Pain and Headache Reports. Stecco A et al.
Who and what was studiedReview of fascia biology and its hyaluronan-rich matrix in relation to myofascial pain syndrome.
What it foundArgues that the participation of fascia in myofascial pain syndrome has often been neglected, and summarises how alterations in the hyaluronan-rich matrix, fibroblasts and collagen composition could produce the pathological changes seen after trauma.
Study notesNarrative review.
2015ReviewViscoelastic properties of hyaluronan in physiological conditionsF1000Research. Cowman MK et al.
Who and what was studiedPhysical-chemistry review of hyaluronan solutions in and beneath deep fascia.
What it foundExplains the physics behind densification. Hyaluronan solutions are highly viscous and non-Newtonian; changes in concentration, molecular weight or covalent modification during inflammation can have dramatic effects on the sliding of fascia. Immobility can increase hyaluronan concentration and viscosity and reduce lubrication and layer movement of connective tissue and muscle layers, and inflammation can raise viscosity further.
Study notesReview of physical properties; not a patient study.
2022ReviewDensification: hyaluronan aggregation in different human organsBioengineering. Stecco A, Cowman M, Pirri N, Raghavan P, Pirri C.
Who and what was studiedNarrative review of hyaluronan aggregation across organs.
What it foundReports that hyaluronan aggregation (densification) has been described in liver, eye, lung, kidney, blood vessel, muscle, fascia and skin, and that in all of these it raises extracellular matrix viscosity, causing stiffness and organ dysfunction. Notes that fibrosis may follow densification in the long term in some organs, and that dynamic ultrasound and elastography can detect it early.
Study notesNarrative review across organs.
2022ReviewPathophysiological and therapeutic roles of fascial hyaluronan in obesity-related myofascial diseaseInternational Journal of Molecular Sciences. Ugwoke CK, Cvetko E, Umek N.
Who and what was studiedNarrative review from an independent group (University of Ljubljana).
What it foundReviews how chronic inflammation, oxidative stress and altered adipose metabolism can change the physical and biological properties of fascial hyaluronan, and restates the distinction between reversible densification and difficult-to-reverse fibrosis. Notes that hyaluronan-based treatments are used in orthopaedic conditions that share mechanisms with myofascial disease.
Study notesObesity-focused review.
2024Animal or lab studyThe impact of sciatic nerve injury on extracellular matrix of lower limb muscle and thoracolumbar fasciaInternational Journal of Molecular Sciences. Zhao X et al.
Who and what was studied18 rats: 12 with unilateral sciatic nerve injury and 6 controls; hyaluronan and collagen measured in muscle and thoracolumbar fascia at 6 weeks.
What it foundAfter a nerve injury in one leg, hyaluronan in the thoracolumbar fascia fell on both sides (left 66.95 ± 20.08 and right 112.66 ± 30.53 µg/g versus 167.18 ± 31.13 µg/g in healthy rats) while collagen rose (115.89 ± 28.18 and 90.43 ± 20.83 versus 47.51 ± 7.82 µg/g). Muscle hyaluronan also fell by about a third. Shows that nerve injury changes fascial matrix at a distance from the injury.
Study notesAnimal study; no pain outcome.
2016Case seriesHuman recombinant hyaluronidase injections for upper limb muscle stiffness in individuals with cerebral injuryEBioMedicine. Raghavan P, Lu Y, Mirchandani M, Stecco A.
Who and what was studied20 patients with unilateral upper-limb spasticity after brain injury; hyaluronidase injections assessed at four time points up to 3–5 months.
What it foundTests the idea that hyaluronan accumulation in muscle causes stiffness. After injections of the enzyme that breaks down hyaluronan, passive movement at all joints and active movement at most joints increased within two weeks and persisted for months, and modified Ashworth scores fell, without producing weakness or clinically significant adverse effects. The hyaluronan that stiffens these muscles is the same hyaluronan that thickens between fascial layers when fascia densifies, and breaking it down restored movement.
Study notesOpen-label case series; the authors call for placebo-controlled trials.
2014Randomized controlled trialUltrasonography in myofascial neck pain: randomized clinical trial for diagnosis and follow-upSurgical and Radiologic Anatomy. Stecco A, Meneghini A, Stern R, Stecco C, Imamura M.
Who and what was studied28 patients with chronic neck pain and 25 healthy subjects; ultrasound thickness of sternocleidomastoid and scalene fascia and its loose and dense sublayers, before and after treatment.
What it foundFascia was significantly thicker in patients. After treatment, pain and fascial thickness both decreased, and the decrease came specifically from the loose connective tissue sublayer, not the dense layer. The authors propose a 0.15 cm sternocleidomastoid fascia thickness as a diagnostic cut-off and conclude the loose connective tissue within fascia may play a role in chronic neck pain.
Study notesSmall trial.
2014Case seriesCould ultrasound and elastography visualise densified areas inside the deep fascia?Journal of Bodywork and Movement Therapies. Luomala T et al.
Who and what was studiedSingle case: a 40-year-old man with subacute calf pain, imaged before and after manual therapy.
What it foundUltrasound and elastography visualised an alteration in layer movement, echogenicity and elasticity of the deep fascia and its change after treatment. Offered as a proof of concept that imaging could give an objective picture of what manual therapists palpate.
Study notesSingle case.
2025Systematic reviewTherapeutic mechanisms of fascia manipulation: a scoping reviewJournal of Back and Musculoskeletal Rehabilitation. Isaji Y et al.
Who and what was studiedScoping review of 11 studies (8 human, 3 animal) on mechanisms of fascia manipulation.
What it foundIn humans, manual therapy reduced unbound water in deep fascia and triggered a transient local inflammatory response; animal studies showed anti-inflammatory effects via cytokine regulation and adenosine receptors. The review concludes that fascia manipulation relieved pain from densification and improved proprioception, with neuromuscular effects lasting up to a week.
Study notesScoping review.
2026ReviewThe myofascial rheostat: hyaluronan molecular weight dynamics and purinergic signalling as a physiological feedback systemFrontiers in Physiology. Kirkness KB et al.
Who and what was studiedNarrative review integrating hyaluronan biology across tissue types.
What it foundDescribes fascia as a hyaluronan-rich adaptive interface that senses and responds to inflammatory cues, and lays out the feedback system in which mechanical loading, inflammatory cytokines, energy availability and clearance mechanisms together control hyaluronan turnover, hydration and viscosity in fascia. The most current account of why fascial hydration rises and falls.
Study notesNarrative review.
2023Animal or lab studyInjecting hyaluronan in the thoracolumbar fascia: a model studyInternational Journal of Biological Macromolecules. Nešporová K et al.
Who and what was studiedRabbit model of the thoracolumbar fascia; ultrasound-guided injection of hyaluronan of different molecular weights, with rheology, tribology and gene expression measured.
What it foundOpens by stating that hyaluronan has been identified as a key component of the densification of thoracolumbar fascia. Adding hyaluronan between the fascial layers improved their lubrication and freedom of movement without triggering fibrosis, which the authors describe as a promising way to restore movement between fascial layers.
Study notesAnimal model.
2022Imaging studyPilot study assessing the effect of Fascial Manipulation on fascial densifications and associated painEuropean Journal of Translational Myology. Hughes E et al.
Who and what was studiedAdults with self-reported painful regions; fascial densifications identified by palpation and measured with diagnostic ultrasound before and after a brief manual intervention.
What it foundDensified fascia could be located by palpation and measured on ultrasound, densification thickness correlated with pain intensity, and a brief intervention on the fascia reduced both the densification thickness and the pain.
Study notesPilot study.
Measuring fascia15 studies
This is where the model meets measurement. Ultrasound and elastography can now measure fascial thickness, stiffness, density and how much adjacent layers move, and the measurements are reproducible. Fascia that was invisible on X-ray and MRI is now something researchers can see and quantify. The most studied case is the lower back, where a 2026 pooled analysis of fourteen imaging studies found the fascia thicker, stiffer and denser in people with chronic pain than in people without, with thickening tracking pain. Studies differ on exactly how layer movement changes, and both sides are listed here.
2026Meta-analysisDifferences in the thoracolumbar fascia between low back pain patients and healthy individuals: a systematic review with meta-analysisSports Medicine – Open. Wilke J et al.
Who and what was studied14 imaging studies (ultrasound and MRI) of moderate-to-high methodological quality comparing thoracolumbar fascia in low back pain patients and asymptomatic controls.
What it foundRelative to controls, low back pain patients had thicker (SMD 0.64, 95% CI 0.41–0.88, 12 studies), stiffer (SMD 0.82, 95% CI 0.34–1.31, 3 studies) and more echogenic (SMD 0.43, 3 studies) thoracolumbar fascia. No pooled effect was found for sliding between fascial layers, because the two studies on it pointed in opposite directions.
Study notesPooled from cross-sectional imaging studies.
2026Systematic reviewThoracolumbar fascia ultrasound and elastography biomarkers in low back pain: a systematic review of associations and responsiveness to interventionEuropean Spine Journal. Schleip R et al.
Who and what was studied14 studies, about 880 participants, of quantitative ultrasound biomarkers of the thoracolumbar fascia in non-specific low back pain.
What it foundSeveral studies reported greater fascial thickness, altered echogenicity or microstructure, and differences in stiffness in chronic low back pain compared with controls. Stiffness findings were inconsistent across elastography methods, and shear-strain findings varied: acute low back pain studies generally reported reduced deformation, while chronic studies reported either reduced or increased shear strain.
Study notesNarrative synthesis of 14 studies.
2024Systematic reviewUltrasound imaging of thoracolumbar fascia: a systematic reviewMedicina. Pirri C et al.
Who and what was studiedSystematic review of ultrasound studies of the thoracolumbar fascia, from inception to April 2024.
What it foundSummarises the parameters that can now be measured on ultrasound (thickness, echogenicity, stiffness, deformation, shear strain, displacement) and the protocols used for diagnosis, treatment monitoring and movement-related change.
Study notesAuthors review work that includes their own.
2025ReviewUltrasonography of the fasciae and common pathologies: the game changerDiagnostics. Pirri C et al.
Who and what was studiedPictorial review of ultrasound findings in common fascial lesions.
What it foundPresents ultrasound as a multiparametric tool for assessing thickness, echogenicity, stiffness, deformation and shear strain of fascia, capable of identifying fascial pathology that is not detectable on physical examination.
Study notesPictorial review; no patient-versus-control data.
2025Anatomical studyUltrasound-guided core needle biopsy of deep fascia: a cadaveric study evaluating feasibility, accuracy and reliabilityClinical Anatomy. Pirri C et al.
Who and what was studiedCadaveric study of ultrasound-guided needle biopsy of the thoracolumbar fascia, fascia lata and crural fascia, with histological confirmation.
What it foundCorrect needle placement was 91.88% (long axis) and 96.22% (short axis) with no significant difference between approaches. The authors conclude the method is feasible, consistent and reliable, opening the way to studying fascial pathology directly in patients rather than only in cadavers.
Study notesCadaveric; not yet validated in living patients.
2009Imaging studyUltrasound evidence of altered lumbar connective tissue structure in human subjects with chronic low back painBMC Musculoskeletal Disorders. Langevin HM et al.
Who and what was studied107 adults: 60 with chronic or recurrent low back pain for more than 12 months and 47 without; groups matched on age, sex, BMI and activity.
What it foundThe first quantitative report of abnormal connective tissue structure in low back pain. The low back pain group had approximately 25% greater perimuscular connective tissue thickness and echogenicity than controls (adjusted for BMI, p<0.01 and p<0.001). The perimuscular connective tissue measured here is the fascia around the back muscles: the first hard evidence that fascia is physically different in people with chronic pain.
Study notesCross-sectional; cannot show cause.
2011Imaging studyReduced thoracolumbar fascia shear strain in human chronic low back painBMC Musculoskeletal Disorders. Langevin HM et al.
Who and what was studied121 adults: 71 with low back pain for more than 12 months and 50 without; ultrasound elasticity imaging of the thoracolumbar fascia during passive trunk flexion.
What it foundShear strain between fascial layers was reduced in the low back pain group: 56.4% ± 3.1% versus 70.2% ± 3.6% in controls, about 20% lower. The main source of the finding that fascial layers move less in chronic low back pain.
Study notesA 2025 study using a different measurement method found the opposite direction of change (see Tomita 2025 below).
2023Imaging studyUltrasound imaging of thoracolumbar fascia thickness: chronic non-specific lower back pain versus healthy subjectsDiagnostics. Pirri C et al.
Who and what was studied92 subjects: 46 with chronic non-specific low back pain and 46 healthy; thoracolumbar fascia thickness at L3 measured in longitudinal and transverse axes.
What it foundFascia was significantly thicker in the low back pain group in both axes (p<0.05). Healthy subjects showed a difference between longitudinal and transverse thickness that was absent in patients, which the authors interpret as the fascia becoming homogeneously thicker and losing adaptability, a sort of "frozen back".
Study notesSingle centre; cross-sectional.
2023Imaging studyUltrasound evidence of altered lumbar fascia in patients with low back painClinical Anatomy. Tamartash H et al.
Who and what was studied131 subjects: 68 with chronic non-specific low back pain and 63 without; sonographic strain imaging of the thoracolumbar fascia at L2–L3 and L4–L5.
What it foundThe low back pain group had a 25–30% lower fascial elastic modulus coefficient than healthy individuals, and there was a strong inverse relationship between pain severity and the elasticity coefficient (r = −0.76, p = 0.004). Age, BMI and sex were not related to the elasticity measure.
Study notesCross-sectional; first study of this elastic coefficient in the thoracolumbar fascia.
2023Randomized controlled trialEffect of remote myofascial release on lumbar elasticity and pain in patients with chronic nonspecific low back painJournal of Chiropractic Medicine. Tamartash H et al.
Who and what was studied32 patients with chronic non-specific low back pain randomised to four sessions of myofascial release either to the lumbar region or to the crural and hamstring fascia of the legs; pain and lumbar elastic modulus measured by ultrasound.
What it foundPain and the elastic coefficient of the lumbar myofascial tissue changed significantly in both groups after treatment (p ≤ 0.0005), with no significant difference between local and remote treatment. Suggests fascial tissue properties measured on ultrasound can change with a mechanical intervention.
Study notesSmall; no untreated control group.
2025Imaging studyThoracolumbar fascia ultrasound shear strain differs between low back pain and asymptomatic individuals: expanding the evidenceInsights into Imaging. Tomita N et al.
Who and what was studied32 participants with non-specific low back pain and 32 controls; ultrasound shear strain and thickness before and after a standardised massage.
What it foundMovement between fascial layers was measurably different in the low back pain group (cumulated shear strain 327.1% ± 106.0 vs 290.2% ± 99.8; maximum 8.1% ± 2.8 vs 7.0% ± 2.4; both p<0.0001), and the elastography measurements correlated with pain and disability. Confirms that fascial mechanics are altered in low back pain, with the direction of change differing from the 2011 Langevin study.
Study notesDifferent measurement method from the 2011 study; groups differed in age.
2024Imaging studyShear wave elastography based analysis of changes in fascial and muscle stiffness in patients with chronic non-specific low back painFrontiers in Bioengineering and Biotechnology. Liu K et al.
Who and what was studied30 patients with chronic non-specific low back pain and 32 healthy controls, all in their late twenties; shear-wave elastography of thoracolumbar fascia, erector spinae and multifidus.
What it foundThe low back pain group had significantly higher shear modulus of the thoracolumbar fascia at L4–5 bilaterally (left p = 0.014, d = 0.64; right p = 0.002, d = 0.86), as well as higher stiffness in the underlying muscles. Correlations with pain and disability were examined.
Study notesYoung sample; cross-sectional.
2025Imaging studyReliability of shear wave elastography for cervical and lumbar fascia stiffness and thickness in healthy and chronic neck and low back pain subjectsJournal of Bodywork and Movement Therapies. Zandi S et al.
Who and what was studied15 patients with concurrent neck and low back pain and 15 healthy controls; repeated shear-wave elastography of cervical and lumbar fascia.
What it foundTest-retest reliability for fascia stiffness was excellent (ICC ≥ 0.90) and for thickness good to excellent (ICC ≥ 0.80), so the measurement is reproducible. Patients had significantly thicker lumbar fascia than controls (p = 0.002).
Study notesSmall comparison group; mainly a reliability study.
2023Imaging studyThe relationship between clinical examination measures and ultrasound measures of fascia thickness surrounding trunk muscles or lumbar multifidus fatty infiltrationsJournal of Anatomy. Larivière C et al.
Who and what was studied70 participants with low back pain; ultrasound thickness of the thoracolumbar fascia and the connective tissue between the abdominal wall muscles, alongside physical tests and questionnaires.
What it foundDocuments that chronic low back pain involves remodelling of lumbar soft tissues, including thickness changes of the thoracolumbar fascia and perimuscular connective tissues, and explores which clinical measures these ultrasound findings relate to.
Study notesExploratory; no healthy control group.
2024Imaging studyUltrasound evaluation of deep fascia thickness: reliability and association with clinically evaluated changesJournal of Bodywork and Movement Therapies. Schadmy Levy S et al.
Who and what was studied21 healthy adults for reliability testing and 15 for comparison of fascial thickness at sites of restricted fascial movement versus the normal opposite side, measured by a blinded assessor.
What it foundUltrasound measurement of deep fascia thickness was reliable, and fascia was significantly thicker at sites where movement restriction (densification) was found by palpation than at the same site on the unaffected side. What a trained hand feels as densified fascia shows up as thicker fascia on imaging.
Study notesHealthy volunteers.
Fascia in chronic pain and stiffness11 studies
If fascia can generate pain signals and can be measured as densified in people with pain, the next question is what happens when the fascia itself is treated. The studies here are the general evidence: reviews that place fascia at the centre of chronic pain and stiffness, and trials in which acting on the fascia directly, by separating its layers with fluid, anaesthetising it, or releasing it by hand, relieved pain. Emerging research is showing more and more that fascia is a part of chronic pain and stiffness conditions, and the condition-by-condition evidence follows in the next section.
2022ReviewThe deep fascia and its role in chronic pain and pathological conditions: a reviewClinical Anatomy. Kondrup F, Gaudreault N, Venne G.
Who and what was studiedState-of-the-art review from McGill and Sherbrooke (independent of the densification model's originators).
What it foundIdentifies five main deep fascia pathologies: chronic low back pain, chronic neck pain, Dupuytren's disease, plantar fasciitis and iliotibial band syndrome. Across these, pathological fascia is characterised by increased tissue stiffness, altered myofibroblast activity and extracellular matrix, increased density and sensitisation of nociceptive nerve fibres, and markers of inflammation.
Study notesNarrative review.
2025ReviewExploring fascia in myofascial pain syndrome: an integrative model of mechanismsFrontiers in Pain Research. Gromakovskis V.
Who and what was studiedConceptual narrative review of anatomical, histological, imaging, biomechanical and clinical studies published 2000–2025.
What it foundConcludes that fascia is richly innervated by nociceptors and sympathetic fibres and undergoes pathological changes in myofascial pain syndrome; imaging and histology confirm fibrosis, densification and inflammatory activity in symptomatic fascia. Proposes impaired sliding, abnormal mechanotransduction and neuroinflammatory sensitisation as the pathways from fascia to pain.
Study notesSingle-author conceptual review.
2022Systematic reviewScoping review and interpretation of myofascial pain/fibromyalgia syndrome: an attempt to assemble a medical puzzlePLOS ONE. Plaut S.
Who and what was studiedScoping review of 799 records across MEDLINE, EMBASE, Cochrane, PEDro and medRxiv.
What it foundFinds that fascia can adapt to various states by reversibly changing its biomechanical and physical properties, that myofibroblasts play a role in sustained myofascial tension, and that movement and mechanical interventions treat and prevent myofascial pain while sedentary living predisposes to it. Proposes a mechanical model ("fascial armoring") for how myofascial pain might evolve into fibromyalgia.
Study notesInterpretive; the model is proposed, not tested.
2024ReviewUltrasound-guided fascial plane blocks in chronic pain: a narrative reviewJournal of Anesthesia, Analgesia and Critical Care. Marrone F et al.
Who and what was studiedSystematic literature search (2010–February 2024) of trials, observational studies and case reports of fascial plane blocks for chronic pain.
What it foundEvidence for fascial plane blocks in persistent post-surgical, neuropathic, musculoskeletal-myofascial and cancer-related pain is increasing, though still heavily limited to case reports and series. The authors note the blocks are broadening their role in chronic pain as part of multimodal strategies or as alternatives to conventional drugs or opioids.
Study notesMostly low-level primary evidence.
2025Randomized controlled trialEfficacy of ultrasound-guided myofascial hydrodissection technique in myofascial pain syndrome of upper trapeziusScientific Reports. Chen Y et al.
Who and what was studied41 patients with upper trapezius myofascial pain syndrome randomised to saline hydrodissection of the fascial plane or lidocaine trigger point injection; 12-week follow-up.
What it foundPain fell significantly with both hydrodissection (effect size r = 0.716, p<0.001) and trigger point injection (r = 0.604, p<0.001), with comparable improvements in McGill pain scores and neck disability, and no adverse events. Separating the fascial layers with fluid performed as well as an anaesthetic injection.
Study notesSmall; single-blind.
2025Case seriesUltrasound-guided hydro-dissection of the superficial fascia for cervical myofascial pain: a case seriesJournal of Clinical Ultrasound. Razaq S et al.
Who and what was studiedThree patients with cervical myofascial pain unresponsive to first-line conservative treatment.
What it foundDescribes hydrodissection of the cervical superficial fascia under ultrasound guidance, and discusses the superficial fascia, with its plexiform intrinsic neural network, as a potential pain generator and treatment target in chronic cervical myofascial pain, cervicogenic dizziness and non-dermatomal paraesthesias.
Study notesn = 3; no control.
2015Randomized controlled trialFascial Manipulation for chronic aspecific low back pain: a single blinded randomized controlled trialF1000Research. Branchini M et al.
Who and what was studied24 subjects with chronic non-specific low back pain randomised to a guideline-based physiotherapy programme with or without Fascial Manipulation; eight treatments over four weeks with 1- and 3-month follow-up.
What it foundPatients receiving Fascial Manipulation showed statistically and clinically significant improvements in pain, function and wellbeing at the end of care, and in pain in the medium term, compared with the physiotherapy-only group. The authors note that several studies indicate strong correlations between fascial thickness and low back pain.
Study notesSmall trial.
2017ReviewThe lumbodorsal fascia as a potential source of low back pain: a narrative reviewBioMed Research International. Wilke J et al.
Who and what was studiedNarrative review of histological, experimental and imaging evidence on the lumbodorsal fascia.
What it foundSummarises that histology shows pain-sensing free nerve endings in the fascia which change morphologically in chronic pain, that stimulating the fascia in living people increases spinal neuron excitability, and that this sensitisation could be driven by microinjury or inflammation in the fascia. Concludes the data point toward a significant role of fascia in pain.
Study notesNarrative review.
2026Systematic reviewThe stress-fascia-pain axis in myofascial pain syndrome: a mechanistic integrative reviewFrontiers in Pain Research. Gür A et al.
Who and what was studiedPRISMA-based integrative review of human, translational and animal studies on myofascial pain up to February 2026.
What it foundBrings trigger-point biochemistry, fascial dysfunction, stress hormones, autonomic imbalance and altered pain processing into a single account of why myofascial pain persists and recurs, and why a muscle-only model cannot explain it. Fascia and the stress response are treated as linked drivers of chronic pain.
Study notesSingle-reviewer screening.
2021Meta-analysisMyofascial release for chronic low back pain: a systematic review and meta-analysisFrontiers in Medicine. Wu Z et al.
Who and what was studied8 randomised controlled trials, 375 patients, of myofascial release for chronic low back pain.
What it foundWorking on the fascia significantly reduced pain (SMD −0.37, p = 0.01) and improved physical function (SMD −0.43, p = 0.007) compared with controls.
Study notesPooled effect sizes are moderate.
2024Meta-analysisEffectiveness of myofascial release for adults with chronic neck pain: a meta-analysisPhysiotherapy. Overmann L et al.
Who and what was studied10 randomised controlled trials, 549 participants, rated good to excellent in methodological quality.
What it foundMyofascial release produced a significant reduction in pain (p = 0.03) and improved neck rotation and side-bending compared with other treatments.
Study notesEffects described as modest.
Fascia by condition15 conditions
For each condition below, the studies listed measured or examined fascia in people with that condition, or are the papers that first proposed a fascial mechanism for it. Conditions are named because the research names them, not as a claim that Lissom™ treats them.
Fibromyalgia12 studies
Two 2025 imaging studies found the tissue around the trapezius measurably altered and stiffer in fibromyalgia, with stiffness tracking pain, in a condition long described as having nothing to see. Biopsy studies going back to 1990 found altered collagen, immune deposits and more mast cells in the connective tissue of fibromyalgia patients, and researchers have proposed inflamed, densified fascia as the peripheral source of the persistent signal that drives the pain.
2010ReviewFascia: a missing link in our understanding of the pathology of fibromyalgiaJournal of Bodywork and Movement Therapies. Liptan GL.
Who and what was studiedHypothesis paper.
What it foundProposes that inflammation of the fascia is the source of the persistent peripheral input that leads to central sensitisation in fibromyalgia. Cites biopsy studies that found increased collagen and inflammatory mediators in the connective tissue surrounding muscle cells in fibromyalgia patients, and notes fibroblasts secrete IL-6 in response to strain.
Study notesHypothesis paper.
2023ReviewThe widespread myofascial pain of fibromyalgia is sympathetically maintained and immune mediatedJournal of Bodywork and Movement Therapies. Liptan G.
Who and what was studiedHypothesis paper integrating newer immune findings with known myofascial pathology.
What it foundStates that fibromyalgia fascial biopsies demonstrate elevated inflammatory and oxidative stress markers and increased endomysial collagen deposition, alongside impaired muscle relaxation and elevated intramuscular pressure. Proposes a unifying model in which sympathetic hyperactivity, impaired tissue healing and autoantibodies converge on myofascial tissue.
Study notesHypothesis paper.
2025Imaging studyStructural changes in the upper trapezius muscle of fibromyalgia patients identified by quantitative ultrasonographyRheumatology International. Meral HB et al.
Who and what was studied34 women with fibromyalgia and 34 healthy controls; quantitative B-mode ultrasound of the upper trapezius and the myofascial tissue around it, correlated with pain and symptom scores.
What it foundFibromyalgia patients showed significantly altered tissue texture (higher total blob size and blob size per mm², both p<0.001) and increased echointensity (p = 0.009) compared with controls, and pain scores predicted the degree of change. The first imaging study to reliably show measurable tissue change in a condition long described as having nothing to see.
Study notesMeasures the trapezius and its surrounding myofascial tissue rather than an isolated fascial layer.
2025Imaging studySkin layer thickness, muscle elasticity and their effects on pain level in fibromyalgia patientsClinics. Akan S et al.
Who and what was studied89 women with fibromyalgia and 36 healthy controls; B-mode ultrasound and compression sonoelastography of the trapezius region, skin and subcutaneous tissue.
What it foundThe trapezius region was thicker and measurably stiffer on elastography in fibromyalgia (p<0.05 and p<0.001), and stiffness correlated strongly with pain (r = 0.661, p<0.001). Skin was thinner in patients. Stiffer tissue, more pain: measured rather than theorised. Elastography measures the stiffness of the muscle together with the fascia that wraps it; stiffer myofascial tissue tracked pain in fibromyalgia.
Study notesElastography of the trapezius and surrounding tissue.
1997Anatomical studyDermal IgG deposits and increase of mast cells in patients with fibromyalgiaScandinavian Journal of Rheumatology. Eneström S et al.
Who and what was studiedSkin biopsies from 25 fibromyalgia patients, 5 healthy controls, 8 rheumatoid arthritis patients and 9 people with local pain after whiplash; immunofluorescence for IgG and collagen types, mast cell counts.
What it foundFibromyalgia biopsies had significantly more IgG deposits in the dermis and vessel walls, higher reactivity for collagen III, and a higher number of mast cells, with the proportion of degranulated mast cells correlating with IgG scores. The authors conclude the findings support neurogenic inflammation in the connective tissue in fibromyalgia. The dermis is a connective tissue layer continuous with the superficial fascia beneath it; the altered collagen and inflammatory cells found here are the kind of change the fascial model predicts.
Study notesSmall biopsy study.
1990Anatomical studyAttachment of IgG to dermal extracellular matrix in patients with fibromyalgiaClinical and Experimental Rheumatology. Eneström S et al.
Who and what was studiedSkin biopsies from people with primary fibromyalgia, healthy controls, and patients with lupus and rheumatoid arthritis.
What it foundIgG deposits localised to collagen bundles and extracellular matrix in fibromyalgia skin but not in healthy controls, which the authors say may point to a qualitative alteration of the connective tissue matrix in fibromyalgia, possibly linked to tissue hypoxia or capillary leakage. Points to a physical alteration of the connective tissue matrix in fibromyalgia, decades before fascia was on the research agenda.
Study notesEarly biopsy study.
2021Meta-analysisEffectiveness of myofascial release on pain, sleep, and quality of life in patients with fibromyalgia syndrome: a systematic reviewComplementary Therapies in Clinical Practice. Ughreja RA et al.
Who and what was studied6 trials, 279 fibromyalgia patients, of myofascial release alone or with exercise.
What it foundWorking on the fascia had a large, significant effect on fibromyalgia pain after treatment (SMD −0.81, p<0.00001) that was still moderate six months later (SMD −0.61, p = 0.0003), with improvements in sleep and quality of life. If treating the fascia relieves fibromyalgia pain, the fascia is part of fibromyalgia pain.
Study notesMore high-quality trials called for.
2026Meta-analysisWhat are the effects of connective tissue massage vs. myofascial release on fibromyalgia pain? Systematic review with meta-analysisComplementary Therapies in Medicine. Ide FC et al.
Who and what was studied10 studies comparing connective tissue massage, therapist-applied myofascial release and self-myofascial release in fibromyalgia.
What it foundStates that dysfunctions of the muscle fascia contribute to the pathogenesis of fibromyalgia and directly influence pain and central sensitisation. Myofascial release significantly reduced pain (SMD −1.16, p = 0.0003), a large effect, while general connective tissue massage did not.
Study notesHeterogeneous trials.
2015Meta-analysisEffectiveness of different styles of massage therapy in fibromyalgia: a systematic review and meta-analysisManual Therapy. Yuan SL et al.
Who and what was studied10 controlled trials of massage in fibromyalgia, 1990–2013.
What it foundOf all the manual approaches compared, myofascial release had large positive effects on pain and medium effects on anxiety and depression, with pain relief maintained in the medium term, and also improved fatigue, stiffness and quality of life. Swedish massage, which does not target fascia, did not improve outcomes.
Study notesPooled from 145 participants.
2019Meta-analysisA systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgiaSeminars in Arthritis and Rheumatism. Grayston R et al.
Who and what was studied8 studies, 222 fibromyalgia patients, with skin biopsy or corneal microscopy.
What it foundPooled prevalence of small nerve fibre pathology in fibromyalgia was 49%, with the authors proposing a new paradigm in which the peripheral nervous system is involved. These small fibres are the ones that run through, and are wired into, the fascia.
Study notesModerate heterogeneity.
2014Human experimental studyChronic widespread pain: increased glutamate and lactate concentrations in the trapezius muscle and plasmaClinical Journal of Pain. Gerdle B et al.
Who and what was studied17 women with chronic widespread pain (including fibromyalgia) and 24 pain-free women; microdialysis sampling of the fluid inside the trapezius tissue.
What it foundThe interstitial fluid, the fluid that bathes the tissue between muscle and fascia, had significantly higher lactate and glutamate in chronic widespread pain, and these tissue-level concentrations, not the blood levels, correlated with pain thresholds. Supports the view that the central changes in fibromyalgia are maintained by input from the peripheral tissue.
Study notesSmall study.
Myofascial pain syndrome3 studies
Recent reviews place fascia at the centre of myofascial pain, and a 2025 randomised trial found that separating the fascial layers with fluid relieved pain as well as an anaesthetic injection.
2023Imaging studyViscoelasticity in trapezius myofascial pain syndrome: quantitative assessment using real-time shear-wave elastographyAnnals of Medicine. Hao CJ et al.
Who and what was studied31 patients with trapezius myofascial pain syndrome and 31 volunteers; shear-wave elastography of 123 trapezius muscles.
What it foundTissue thickness and blood flow did not differ, but shear-wave velocity, the measure of stiffness, was significantly higher in myofascial pain patients. The tissue is not thicker in myofascial pain; it is stiffer.
Study notesMeasured in the trapezius and its fascia together.
- 2025Exploring fascia in myofascial pain syndrome: an integrative model of mechanismsFrontiers in Pain Research. Gromakovskis V.
- 2025Efficacy of ultrasound-guided myofascial hydrodissection technique in myofascial pain syndrome of upper trapeziusScientific Reports. Chen Y et al.
Hypermobility and hEDS9 studies
Imaging shows thicker fascia and markedly reduced movement between fascial layers in Ehlers-Danlos syndrome, elastography shows altered tissue properties throughout, and cell studies show the connective tissue cells have converted to the contractile state that drives fascial tension. A 2025 review proposes reframing hEDS as a disorder of fascial remodelling.
2021Imaging studyFascial thickness and stiffness in hypermobile Ehlers-Danlos syndromeAmerican Journal of Medical Genetics Part C. Wang TJ et al.
Who and what was studied65 people examined prospectively: 26 with hEDS and 39 with chronic neck, knee or back pain without hEDS; B-mode ultrasound and strain elastography of the sternocleidomastoid deep fascia, iliotibial tract and iliac fascia.
What it foundhEDS subjects had a higher mean thickness of the sternocleidomastoid deep fascia than non-hEDS subjects. Iliac fascia and iliotibial tract thickness did not differ. Elastography suggested that in myofascial pain the fascia softens relative to muscle, a change that was less pronounced in hEDS.
Study notesComparison group had chronic pain without hEDS.
2023Imaging studyChange in layer movement properties of the iliotibial tract in hypermobile Ehlers-Danlos syndromeJournal of Ultrasound. Wang TJ et al.
Who and what was studied9 subjects: hEDS, lower-limb pain without hEDS, and pain-free controls; ultrasound tissue displacement of the iliotibial tract.
What it foundShear strain was 46.2% in hEDS, versus 89.5% in people with lower-limb pain without hEDS and 121.1% in pain-free controls. The authors suggest extracellular matrix changes in hEDS may show up as reduced movement between fascial planes.
Study notesPilot; n = 9.
2025ReviewFascial pathophysiology in hypermobility spectrum disorders and hypermobile Ehlers-Danlos syndrome: a review of emerging evidenceInternational Journal of Molecular Sciences. Wang TJ, Stecco A, Hakim AJ, Schleip R.
Who and what was studiedNarrative review of molecular, histological and biomechanical findings.
What it foundReports that transcriptomic and imaging studies reveal consistent abnormalities in fascial thickness, intermovement between fascial layers, myofibroblast activation, tendon elongation and tissue stiffness in these disorders, and proposes reframing hEDS and HSD as disorders of pathological fascial remodelling.
Study notesReview.
2025Imaging studyConnective tissue changes in Ehlers-Danlos syndromes with and without axial spondyloarthropathyJournal of Ultrasound. Wang TJ et al.
Who and what was studied37 people with Ehlers-Danlos syndrome, 23 with co-occurring spondyloarthritis and 14 without; ultrasound and strain elastography of the sternocleidomastoid and thoracolumbar fascia.
What it foundThoracolumbar fascia was thickened in both groups, more so where inflammatory arthritis was also present (median 5.6 mm versus 4.4 mm, p = 0.002). The authors conclude fascial remodelling reflects overlapping inflammatory and mechanical processes and that ultrasound can monitor connective tissue change in this population.
Study notesNo non-EDS control group in this study.
2018Animal or lab studyDermal fibroblast-to-myofibroblast transition is a common feature for hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disordersBiochimica et Biophysica Acta: Molecular Basis of Disease. Zoppi N et al.
Who and what was studiedCultured skin fibroblasts from hEDS and HSD patients.
What it foundConnective tissue cells from hEDS and HSD patients showed a disarray of several extracellular matrix components and had converted to a contractile myofibroblast-like state, with dysregulated expression of genes involved in connective tissue homeostasis and in inflammatory and pain responses. The same cell change that drives fascial tension is present in hEDS tissue.
Study notesCell culture study.
2022Animal or lab studyRNA-seq of dermal fibroblasts from patients with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disordersCells. Ritelli M et al.
Who and what was studiedGene expression profiling of hEDS and HSD skin fibroblasts by RNA sequencing, qPCR and immunofluorescence.
What it foundBoth hEDS and HSD cells share generalised extracellular matrix disarray, myofibroblast differentiation and dysregulated expression of growth factors, structural matrix components and matrix-modifying enzymes. The authors propose a model in which unbalanced matrix remodelling sets off a cycle of matrix degradation and inflammation that impairs connective tissue throughout the body. These are the cells that build and maintain fascia; in hEDS they are switched into the contractile, matrix-degrading state that drives fascial tension and loss of movement between layers.
Study notesCell study; supports the pathway rather than measuring tissue in patients.
2019Imaging studyThe impact of hypermobility spectrum disorders on musculoskeletal tissue stiffness: an exploration using strain elastographyClinical Rheumatology. Alsiri N et al.
Who and what was studied21 people with hypermobility spectrum disorder and 22 controls; strain elastography of five muscles and two tendons.
What it foundStrain index was significantly reduced in the hypermobility group in the brachioradialis (0.43 vs 0.59), patellar tendon (0.30 vs 0.44) and Achilles tendon (0.24 vs 0.49), with more soft-tissue signal in the biceps and Achilles. Direct imaging evidence that connective tissue properties are measurably different in hypermobility. Strain elastography measures the elasticity of muscle together with its fascial wrapping and of the tendons, which are continuous with fascia; the connective tissue system is measurably different in hypermobility.
Study notesExploratory cross-sectional study.
2022Human experimental studyExploring pain mechanisms in hypermobile Ehlers-Danlos syndrome: a case-control studyEuropean Journal of Pain. De Wandele I et al.
Who and what was studied20 women with hEDS and 20 matched controls; pressure pain thresholds, temporal summation, conditioned pain modulation and exercise-induced hypoalgesia.
What it foundThe hEDS group had lower pressure pain thresholds and significantly more temporal summation after repeated pressure, with reduced exercise-induced pain relief at the quadriceps. Pain is described as the most prevalent and disabling symptom in hEDS, and this shows a sustained peripheral input being amplified. A persistently amplified response to pressure is what a sustained input from a sensitised tissue, such as densified fascia, produces.
Study notesSmall experimental study.
2019Imaging studyJoint hypermobility among female patients presenting with chronic myofascial pelvic painPM&R. Hastings J et al.
Who and what was studied318 women diagnosed with chronic myofascial pelvic pain at a tertiary centre; 77 with generalised hypermobility spectrum disorder and 241 without.
What it found24% of women with chronic myofascial pain met criteria for generalised hypermobility spectrum disorder, well above the general population, with hypermobility linked to 7.5 times the odds of low back pain and 3 times the odds of hip pain. Myofascial pain and hypermobility travel together.
Study notesRetrospective chart review.
POTS and dysautonomia4 studies
POTS is now firmly associated with connective tissue disorders. In cohort after cohort, roughly a third to a half of POTS patients meet criteria for hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder, which puts the same fascial changes documented in hEDS at the centre of a large share of POTS.
2020Imaging studyPrevalence of hypermobile Ehlers-Danlos syndrome in postural orthostatic tachycardia syndromeAutonomic Neuroscience. Miller AJ et al.
Who and what was studied91 POTS patients evaluated against the 2017 hEDS diagnostic checklist.
What it found31% of POTS patients met full clinical criteria for hEDS and a further 24% had generalised joint hypermobility without meeting full criteria, so more than half showed a connective tissue disorder. The authors call this important for understanding the mechanisms connecting the two syndromes. hEDS is a disorder of connective tissue, and the fascial thickening and loss of movement between fascial layers documented in hEDS apply to the large share of POTS patients who have it.
Study notesSingle-centre cohort.
2021Imaging studyPrevalence of joint hypermobility syndromes in pediatric postural orthostatic tachycardia syndromeAutonomic Neuroscience. Boris JR et al.
Who and what was studied362 children and adolescents with POTS evaluated for Ehlers-Danlos syndrome and hypermobility spectrum disorder.
What it found22.7% had Ehlers-Danlos syndrome and a further 39.0% had hypermobility spectrum disorder, so about six in ten young people with POTS had a diagnosable connective tissue disorder. Those with EDS had an earlier age of symptom onset. The connective tissue disorders found in most of these young POTS patients are the same disorders in which fascia has been shown to be thicker and less mobile.
Study notesLarge clinic series.
2025Imaging studyAssociation of postural orthostatic tachycardia syndrome, hypermobility spectrum disorders, and mast cell activation syndrome in young patientsFrontiers in Neurology. Yao L et al.
Who and what was studiedRecords of 392 patients with orthostatic intolerance, of whom 100 met POTS criteria, reviewed for joint hypermobility disorders and mast cell activation.
What it foundDescribes the association of POTS with hypermobility disorders and mast cell activation as now firmly established. Depending on the definition used, 13% to 34% of POTS patients had a joint hypermobility disorder and up to 87% met clinical criteria for mast cell activation, and patients responded to therapy regardless of how strictly they were defined. A syndrome this closely tied to hypermobility is a syndrome tied to connective tissue, and fascia is the connective tissue that has been measured as abnormal in hypermobility.
Study notesRetrospective review.
- 2024Fascia as a regulatory system in health and diseaseFrontiers in Neurology. Slater AM et al.
Sjögren's syndrome4 studies
Between 15% and 45% of people with Sjögren's meet full criteria for fibromyalgia, and that widespread pain and stiffness does not track the disease's inflammatory markers. It is the myofascial pain pattern, and the fascia research under fibromyalgia and myofascial pain applies to it.
2016Imaging studyPrevalence and clinical impact of fibromyalgia in patients with primary Sjögren's syndromeClinical and Experimental Rheumatology. Choi BY et al.
Who and what was studied100 consecutive primary Sjögren's patients assessed for fibromyalgia by 2010 ACR criteria, with disease activity and patient-reported indices.
What it found31% of Sjögren's patients met criteria for fibromyalgia. Widespread pain and symptom severity correlated strongly with the Sjögren's patient-reported index (r = 0.65 and 0.72). Nearly a third of people with Sjögren's carry the widespread myofascial pain pattern.
Study notesCross-sectional study.
2017Imaging studyFibromyalgia prevalence and associated factors in primary Sjögren's syndrome patients in a large cohort from the Spanish Society of Rheumatology registryClinical and Experimental Rheumatology. Torrente-Segarra V et al.
Who and what was studied437 primary Sjögren's patients from the national SJOGRENSER registry.
What it found14.6% had fibromyalgia, and those patients had significantly more fatigue, joint pain, constitutional symptoms and higher disease activity scores, with no difference in laboratory or histological inflammation. The pain and stiffness burden in Sjögren's does not track the inflammatory markers. Pain and stiffness that do not track inflammation are the signature of the myofascial pain pattern, in which the source is the fascia rather than the autoimmune process.
Study notesRegistry study.
2025Imaging studyFrom autoimmune sialadenitis to central pain: hypothesising shared pathogenesis for fibromyalgia and primary Sjögren's diseaseInternational Journal of Molecular Sciences. Jaskólska MM et al.
Who and what was studied97 consecutive primary Sjögren's patients; fibromyalgia questionnaires, nerve conduction studies, EMG and MRI.
What it foundNearly half (45%) met diagnostic criteria for fibromyalgia. Fibromyalgia did not correlate with polyneuropathy, myopathy or laboratory findings, and the authors conclude it should be treated as a comorbidity needing a different therapeutic approach from the autoimmune disease itself. Nearly half of Sjögren's patients carry fibromyalgia, the condition in which fascial inflammation and stiffness have been proposed and measured as the peripheral pain source.
Study notesSingle-centre study.
2001Imaging studyWidespread pain and Sjögren's syndromeJournal of Rheumatology. Pendarvis WT, Pillemer SR.
Who and what was studied92 patients evaluated in a Sjögren's syndrome clinic, classified by objective criteria and screened for widespread pain by 1990 ACR definition.
What it foundExplored the association between Sjögren's syndrome and widespread pain, the defining feature of fibromyalgia, in a clinic population classified by objective Sjögren's criteria. Widespread pain is the myofascial pain pattern, and this study documents it as a feature of Sjögren's rather than a separate coincidence.
Study notesClinic-based study.
Osteoarthritis12 studies
Cartilage and bone changes do not explain osteoarthritis pain: in a 10-year study of nearly 5,000 patients, imaging predicted at most a quarter of symptoms. The connective tissue around the joint does: fibrosis of the joint lining contributes heavily to pain and stiffness, stiffness of the posterior capsule limits movement, and fascial thickening tracks disease duration.
2022Imaging studyUltrasonic evaluation of plantar fascia in patients with osteoarthritis of the kneeMedicine. Liu Z et al.
Who and what was studiedKnee osteoarthritis surgery patients split by disease duration, plus healthy controls; ultrasound plantar fascia thickness.
What it foundPlantar fascia was thicker in knee osteoarthritis than in controls: 0.44 ± 0.10 cm (left) and 0.42 ± 0.10 cm (right) in long-duration disease and 0.37 and 0.34 cm in short-duration disease, versus 0.30 cm in controls. Suggests fascial change accompanies knee osteoarthritis, though at a distant site.
Study notesPlantar fascia measured, at a distance from the knee.
2013Imaging studyDiscordance between pain and radiographic severity in knee osteoarthritis: findings from quantitative sensory testing of central sensitizationArthritis & Rheumatism. Finan PH et al.
Who and what was studied113 people with knee osteoarthritis grouped by pain level and X-ray grade; quantitative sensory testing.
What it foundPain and X-ray severity did not line up: 30 patients had high pain with low radiographic damage and 27 had low pain with high damage. The high-pain, low-damage group showed heightened pain sensitivity, the signature of a persistent input being amplified, after adjusting for psychological factors, age and sex. When pain outruns the joint damage, the amplified sensitivity points to a persistent input from the soft tissue around the joint, which is where the fascia sits.
Study notesCross-sectional.
2025Imaging studyThe discordance between pain and imaging in knee osteoarthritisJournal of the American Academy of Orthopaedic Surgeons. Hill BG et al.
Who and what was studied4,796 patients with knee osteoarthritis followed for 10 years in the Osteoarthritis Initiative; 24,256 radiographic readings and 2,851 MRI scores modelled against symptom scores.
What it foundNeither radiographic features nor MRI scores predicted patients' pain or symptoms; the best model explained only 15% (X-ray) to 28% (MRI) of symptoms, and prediction got worse as symptoms got more severe. Cartilage and bone changes do not explain most osteoarthritis pain, which is why researchers are looking at the soft tissues around the joint. If the bone and cartilage explain so little of the pain, the connective tissue around the joint, the fascia and capsule, is where the rest has to come from.
Study notesLarge registry analysis.
2015ReviewUnravelling osteoarthritis-related synovial fibrosis: a step closer to solving joint stiffnessRheumatology. Remst DF, Blaney Davidson EN, van der Kraan PM.
Who and what was studiedReview of the factors driving fibrosis of the connective tissue lining the joint in osteoarthritis.
What it foundStates that synovial fibrosis is often found in osteoarthritis and contributes heavily to joint pain and stiffness, the main symptoms of the disease, and reviews the drivers, including TGF-β, connective tissue growth factor and hyaluronan. The synovium is the connective tissue lining of the joint capsule, continuous with the fascia around it; its fibrosis is the joint-level version of fascial densification and stiffening.
Study notesNarrative review.
2025ReviewInfrapatellar fat pad in knee osteoarthritis: a comprehensive review of pathophysiology and targeted therapeutic strategiesInternational Journal of Molecular Sciences. Mallia I et al.
Who and what was studiedReview of the connective tissue and fat structure inside the knee capsule in osteoarthritis.
What it foundReports that the infrapatellar fat pad is now recognised as an active contributor to osteoarthritis through inflammatory mediators that sustain inflammation, fibrotic remodelling and neurogenic pain, and that preclinical research indicates reducing its inflammation and fibrosis could relieve pain. The fat pad sits inside the fibrous capsule and is threaded with connective tissue and nerves; its fibrosis and inflammation are fascial-type changes inside the joint.
Study notesNarrative review.
2016ReviewInflammation of the infrapatellar fat padJoint Bone Spine. Eymard F, Chevalier X.
Who and what was studiedReview of the infrapatellar fat pad in knee osteoarthritis.
What it foundThe fat pad sits between the joint capsule and the synovial membrane, is richly supplied with nerves, and in knee osteoarthritis its inflammation, hypertrophy and fibrosis may be a source of pain. A richly innervated connective tissue structure inside the knee that becomes fibrotic and painful: the fascial mechanism, at the joint.
Study notesNarrative review.
2025Imaging studyInvestigation of the relationship between soft tissue stiffness and maximum knee extension angle in patients with knee osteoarthritisJournal of Biomechanics. Okada S et al.
Who and what was studied66 women over 50 with medial knee osteoarthritis; shear-wave elastography of the posterior capsule, ligament and surrounding muscles.
What it foundStiffness of the medial posterior capsule, the connective tissue at the back of the knee, was significantly associated with how far the knee could extend (p = 0.012). The connective tissue around the joint, not only the joint itself, limits movement in osteoarthritis. The posterior capsule is dense connective tissue continuous with the fascia of the leg; when it stiffens, the knee cannot straighten, which is the stiffness people with osteoarthritis describe.
Study notesCross-sectional.
2023Systematic reviewMyofascial pain as an unseen comorbidity in osteoarthritis: a scoping reviewClinical Journal of Pain. Duarte FCK et al.
Who and what was studied13 low-risk-of-bias studies (6 observational, 7 experimental) on myofascial pain and trigger points in hip and knee osteoarthritis.
What it foundActive myofascial trigger points were more evident in the quadriceps and hamstrings of knee osteoarthritis patients than in healthy people, and treating the myofascial tissue improved pain and function in both hip and knee osteoarthritis compared with sham. Myofascial pain is described as an unseen comorbidity of osteoarthritis.
Study notesScoping review.
2020Imaging studyPrevalence of myofascial trigger points in patients with mild to moderate painful knee osteoarthritisJournal of Clinical Medicine. Sánchez Romero EA et al.
Who and what was studied114 patients with painful knee osteoarthritis examined for myofascial trigger points in six muscle groups.
What it foundMyofascial trigger points were common in every muscle group examined, up to 50% in the tensor fasciae latae, and their number correlated with pain and disability. A measurable share of osteoarthritis pain comes from the myofascial tissue around the joint.
Study notesSecondary analysis.
2017ReviewA myofascial component of pain in knee osteoarthritisJournal of Bodywork and Movement Therapies. Dor A, Kalichman L.
Who and what was studiedCritical review of observational and interventional studies on myofascial pain in osteoarthritis.
What it foundProposes that the well-known mismatch between osteoarthritis pain and X-ray findings is partly explained by pain originating in the myofascial tissue around the joint, and finds initial evidence that myofascial trigger points play a role in the pain and disability of knee osteoarthritis.
Study notesNarrative review.
2025ReviewFibroblast-myofibroblast transition in osteoarthritis progression: current insightsInternational Journal of Molecular Sciences. Peng R et al.
Who and what was studiedReview of the connective tissue cell changes in the joint lining in osteoarthritis.
What it foundGrowing evidence shows that fibrosis of the joint's connective tissue lining drives osteoarthritis progression: its fibroblasts convert to contractile myofibroblasts, deposit excess extracellular matrix and stiffen the joint capsule, which the authors say contributes to chronic inflammation, nerve sensitisation and joint dysfunction. The same cell change that densifies fascia.
Study notesNarrative review.
2024Animal or lab studyModulating mechanobiology as a therapeutic target for synovial fibrosis to restore joint lubricationOsteoarthritis and Cartilage. Bonnevie ED et al.
Who and what was studiedEx vivo and in vitro models of the joint's connective tissue lining under stiff, fibrotic conditions.
What it foundA stiff tissue environment pushed the lining's fibroblasts into a fibrotic state that reduced their production of lubricant, and blocking the cells' contractility restored lubrication. Stiffened connective tissue and loss of lubrication reinforce each other in the osteoarthritic joint. The joint lining's connective tissue cells lose their lubricating function when their environment stiffens, the same relationship between stiffening and loss of lubrication that defines fascial densification.
Study notesLaboratory study.
Nerve injury and neuropathy8 studies
Every nerve travels through fascia. In carpal tunnel syndrome the tissue around the nerve is measurably thicker and up to twice as stiff on elastography, with stiffness tracking severity. In diabetes, fascial thickening precedes and predicts neuropathy. Animal work shows a nerve injury changes hyaluronan and collagen in fascia well away from the injury itself.
2012Imaging studySonographic measurements of subsynovial connective tissue thickness in patients with carpal tunnel syndromeJournal of Ultrasound in Medicine. van Doesburg MHM et al.
Who and what was studiedPatients with carpal tunnel syndrome and healthy controls; ultrasound of the subsynovial connective tissue around the flexor tendons at three levels of the tunnel.
What it foundThe connective tissue surrounding the tendons was thicker in patients at all three levels (0.60–0.63 mm versus 0.46–0.50 mm in controls, p<0.0001). Non-inflammatory fibrosis and thickening of this connective tissue is described as a major pathological finding in idiopathic carpal tunnel syndrome. The subsynovial connective tissue is the fascial sheath that wraps the nerve and tendons inside the tunnel; the nerve is compressed by thickened connective tissue, not by bone.
Study notesThe connective tissue measured is the peritendinous layer inside the tunnel.
2020Systematic reviewSubsynovial connective tissue thickness in carpal tunnel syndrome: a systematic reviewClinical Biomechanics. Robben E et al.
Who and what was studiedSeven studies measuring subsynovial connective tissue thickness in people with and without carpal tunnel syndrome.
What it foundAll four case-control studies showed significantly thicker subsynovial connective tissue in carpal tunnel syndrome. Thickening may precede changes on electrodiagnostic testing, so measuring it could help detect early disease. Thickened connective tissue around the nerve is the consistent finding in carpal tunnel syndrome, the same mechanism the fascial model describes for compressed nerves elsewhere.
Study notesQualitative synthesis only.
2015Anatomical studyThe role of fasciae in Civinini-Morton's syndromeJournal of Anatomy. Stecco C et al.
Who and what was studiedDissection of 11 feet, histology of 10 surgical neuromas, and MRI of 40 patients and 29 controls.
What it foundThe common digital plantar nerve is encased in concentric layers of fibrous and loose connective tissue continuous with the deep foot fascia. On MRI, dorsal fascia thickness was the only measure that differed significantly between patients with the neuroma and controls, pointing to a fascial contribution to this nerve entrapment.
Study notesFoot-specific entrapment.
2014Imaging studyMedian nerve stiffness measurement by shear wave elastography: a potential sonographic method in the diagnosis of carpal tunnel syndromeEuropean Radiology. Kantarci F et al.
Who and what was studied37 patients with carpal tunnel syndrome (60 wrists) and 18 healthy volunteers (36 wrists); shear-wave elastography of the median nerve.
What it foundThe nerve and its surrounding sheath were twice as stiff in carpal tunnel syndrome, 66.7 kPa versus 32.0 kPa in controls (p<0.001), and stiffer still in severe cases (101.4 kPa). A stiffness cut-off diagnosed the condition with 93% sensitivity. Nerve stiffness on elastography reflects the nerve and the connective tissue sheath around it; a nerve twice as stiff is a nerve compressed by densified connective tissue.
Study notesCross-sectional.
2023Imaging studyShear wave elastography is a valuable tool for diagnosing and grading carpal tunnel syndromeSkeletal Radiology. Sernik RA et al.
Who and what was studied58 patients with carpal tunnel syndrome (79 wrists) and 55 healthy controls (63 wrists).
What it foundNerve stiffness was significantly greater in carpal tunnel syndrome (19.4 vs 11.1 kPa, p<0.001) and rose with severity (22.4 kPa in severe cases). The tissue around a compressed nerve measurably stiffens, and the stiffness tracks the damage. Stiffness rising with severity is what the fascial model predicts: the more densified the tissue around the nerve, the worse the neuropathy.
Study notesCross-sectional.
2008Imaging studyPlantar fascia thickness, a measure of tissue glycation, predicts the development of complications in adolescents with type 1 diabetesDiabetes Care. Craig ME et al.
Who and what was studied344 adolescents with type 1 diabetes; plantar fascia thickness on ultrasound at baseline, then complications assessed over a median 3.2 years.
What it foundThickened plantar fascia at baseline, present in 38%, predicted later peripheral neuropathy (odds ratio 2.3) and autonomic neuropathy (odds ratio 4.9), as well as eye and kidney complications. Fascia thickening preceded the neuropathy.
Study notesProspective cohort.
2022Imaging studyIrregularity in plantar fascia, muscle edema and tendon thickness in patients with high risk for diabetic footExperimental and Clinical Endocrinology & Diabetes. Korkmaz BY et al.
Who and what was studied22 patients with diabetes at high risk of diabetic foot and 22 healthy volunteers; MRI of the plantar fascia, tendons and foot muscles.
What it found86% of diabetic patients had irregularity of the plantar fascia versus none of the controls (p<0.001), and the fascia was larger in diabetic patients without arterial disease.
Study notesSmall MRI comparison.
- 2024The impact of sciatic nerve injury on extracellular matrix of lower limb muscle and thoracolumbar fasciaInternational Journal of Molecular Sciences. Zhao X et al.
Polymyalgia rheumatica4 studies
MRI studies show the inflammation in PMR sits in the connective tissue sheaths around the tendons and joint capsules, not in the joints themselves. Localised myofascial inflammation was found in every patient in one series, and the pattern is now specific enough to diagnose PMR.
2019Imaging studyLocalized myofascial inflammation revealed by magnetic resonance imaging in recent-onset polymyalgia rheumaticaJournal of Rheumatology. Laporte JP et al.
Who and what was studied18 patients with active, recent-onset PMR; MRI of shoulder and pelvic girdles at baseline and after 2 and 12 weeks of treatment.
What it foundEvery patient had at least one inflammatory myofascial lesion at baseline: shoulder in 71%, hip in 87%, pubic symphysis in 80%. The lesions were reproducibly identified by blinded radiologists and improved during treatment. Localised myofascial inflammation is described as common in recent-onset PMR.
Study notesPost-hoc analysis of a treatment trial.
2018Imaging studyUse of contrast-enhanced MRI of the pelvis to describe changes at different anatomic sites which are potentially specific for polymyalgia rheumaticaClinical and Experimental Rheumatology. Fruth M et al.
Who and what was studied40 contrast-enhanced pelvic MRIs of patients with PMR, scored by a musculoskeletal radiologist.
What it foundBilateral inflammation of the connective tissue sheaths around the pelvic girdle tendons was found in all patients and is described as the hallmark of PMR, with at least four tendon sites affected on both sides in every case. The inflammation sits in the connective tissue around the tendons, not in the joints. Peritendinous tissue is the fascial sheath around the tendon; PMR's hallmark on MRI is inflamed fascia around the pelvic girdle.
Study notesDescriptive imaging series.
2020Imaging studyDiagnostic capability of contrast-enhanced pelvic girdle magnetic resonance imaging in polymyalgia rheumaticaRheumatology. Fruth M et al.
Who and what was studied120 patients with pelvic girdle pain, 40 with PMR and 80 controls, scored by three blinded radiologists at 19 predefined tendon and capsular sites.
What it foundPMR patients had inflammation at 13.4 ± 2.7 sites versus 4.0 ± 2.3 in controls, and a cut-off of 10 or more inflamed connective tissue sites identified PMR with 95.8% sensitivity. The characteristic pattern of extracapsular connective tissue inflammation can now diagnose PMR on MRI. The diagnostic pattern is extracapsular, in the connective tissue sheaths around tendons and capsules, which is fascia, not joint.
Study notesDiagnostic accuracy study.
2013Imaging studyHigh frequency of capsular knee involvement in polymyalgia rheumatica patients studied by positron emission tomographyRheumatology. Cimmino MA et al.
Who and what was studied25 patients with PMR or giant cell arteritis and 25 matched controls; PET/CT of the knees.
What it found84% of patients showed bilateral inflammation at the knees, and the tracer clearly outlined the fibrous capsule: 90% of capsular connective tissue sites were inflamed versus 23% of sites inside the joint. The inflammation in PMR sits in the fibrous connective tissue around the joint, not in the joint. The fibrous capsule is dense fascial connective tissue; in PMR it is the capsule, not the joint inside it, that is inflamed.
Study notesCross-sectional imaging.
Chronic Lyme3 studies
The Lyme bacterium homes to connective tissue and survives there. Persistent musculoskeletal pain after treatment is confirmed by pooled analysis, and both animal and human studies show the organism living between the collagen fibres of the extracellular matrix after antibiotics have cleared it elsewhere.
2005Meta-analysisPost-Lyme borreliosis syndrome: a meta-analysis of reported symptomsInternational Journal of Epidemiology. Cairns V, Godwin J.
Who and what was studiedFive studies, 504 patients who had had Lyme disease and 530 controls.
What it foundFatigue, musculoskeletal pain and cognitive difficulties were significantly more common in people who had had Lyme disease, with p-values below 0.007 for 8 of 10 symptoms. The authors conclude the evidence is strong that these symptoms may last for years despite antibiotic treatment. Musculoskeletal pain persisting for years after the infection is cleared fits a change in the tissue rather than an ongoing infection.
Study notesPooled analysis.
2013Animal or lab studyDynamics of connective-tissue localization during chronic Borrelia burgdorferi infectionLaboratory Investigation. Imai DM et al.
Who and what was studiedChronically infected mice; tissue localisation of the Lyme bacterium relative to connective tissue components.
What it foundThe Lyme bacterium localises preferentially in the extracellular matrix of connective tissue during persistent infection, colocalising absolutely with the proteoglycan decorin. Even after antibody treatment cleared other sites, spirochetes survived in decorin-rich connective tissue niches and repopulated from there. Decorin is a proteoglycan of the collagen matrix of fascia and other connective tissue; the organism's preferred hiding place is the extracellular matrix of connective tissue.
Study notesAnimal study.
1993Case seriesPersistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosisArthritis & Rheumatism. Häupl T et al.
Who and what was studiedConnective tissue surgically removed from a woman with chronic Lyme disease that had progressed despite antibiotics.
What it foundViable spirochetes were cultured from the ligamentous tissue, and electron microscopy showed them situated between collagen fibres and along fibroblasts. Direct evidence in a human that the organism persists inside connective tissue after treatment. Ligamentous tissue is dense fascial connective tissue; the organism was living between its collagen fibres after antibiotic treatment.
Study notesSingle case.
Post-viral pain (long COVID)8 studies
Almost a third of people meet fibromyalgia criteria six months after COVID-19. Biopsies show why the tissue is involved: fibrosis in 81% of non-hospitalised patients, thickened connective tissue sheaths around the smallest vessels, and structural change that worsens after exertion.
2023Review"Long COVID-19" and viral "fibromyalgia-ness": suggesting a mechanistic role for fascial myofibroblastsFrontiers in Medicine. Plaut S.
Who and what was studiedHypothesis and theory paper.
What it foundNotes that up to 30–40% of convalescent COVID-19 patients develop chronic widespread pain and fatigue and meet 2016 fibromyalgia criteria, and extends the fascial armoring model (contractile myofibroblasts and altered extracellular matrix remodelling in fascia) to explain long COVID's pain, fatigue and autonomic features.
Study notesTheory paper.
2021Imaging studyFibromyalgia: a new facet of the post-COVID-19 syndrome spectrum?RMD Open. Ursini F et al.
Who and what was studied616 people surveyed about six months after COVID-19 using ACR fibromyalgia survey criteria.
What it found30.7% met criteria for fibromyalgia six months after infection. Widespread musculoskeletal pain and stiffness is one of the most common outcomes of the infection. Fibromyalgia is the condition in which fascial inflammation and stiffness have been proposed and measured as the pain source, and a third of post-COVID patients now meet its criteria.
Study notesWeb-based survey.
2023Anatomical studyPost-COVID exercise intolerance is associated with capillary alterations and immune dysregulations in skeletal musclesActa Neuropathologica Communications. Aschman T et al.
Who and what was studiedMuscle biopsies from 11 patients with enduring fatigue and post-exertional malaise after COVID-19, compared with two historical control cohorts.
What it foundPatients had fewer capillaries, thicker capillary basement membranes (the connective tissue sheath around the smallest vessels) and more macrophages in their muscle tissue, with no virus detectable. The authors propose that the infection caused lasting structural changes in the tissue's microvasculature that reduce supply to the tissue. Capillary basement membranes are connective tissue; thickened connective tissue around the smallest vessels reduces the flow of water and nutrients into the tissue, which is what the fascial model says happens after a trigger.
Study notesSmall biopsy series.
2025Anatomical studyMuscle abnormalities in nonhospitalised patients with post-COVID-19 conditionJournal of Cachexia, Sarcopenia and Muscle. Tryfonos A et al.
Who and what was studiedMuscle biopsies from 28 non-hospitalised post-COVID patients and 28 matched healthy controls.
What it foundFibrosis of the tissue was found in 81% of post-COVID patients, along with abnormal fibre shapes, smaller fibres and fewer nuclei per fibre. Structural tissue change is present even in people who were never hospitalised. Fibrosis is connective tissue laid down where it should not be, in the tissue that fascia wraps; it is the structural signature of a tissue that never recovered its supply.
Study notesBiopsy case-control study.
2024Anatomical studyMuscle abnormalities worsen after post-exertional malaise in long COVIDNature Communications. Appelman B et al.
Who and what was studiedLongitudinal case-control study with muscle biopsies before and after an exercise challenge in long COVID patients.
What it foundTissue structure was associated with lower exercise capacity, and severe exercise-induced tissue damage and infiltration of amyloid-containing deposits worsened after post-exertional malaise was induced. Tissue damage that worsens after exertion in a tissue that includes fascia is the physical basis of the post-exertional crash.
Study notesRegistered clinical study.
2022Meta-analysisTime course prevalence of post-COVID pain symptoms of musculoskeletal originPain. Fernández-de-las-Peñas C et al.
Who and what was studied33 studies, 14,639 hospitalised and 11,070 non-hospitalised COVID-19 patients, pooled by follow-up time.
What it foundMusculoskeletal pain persisted through the first year after infection, with pooled prevalence of muscle pain up to 18% and joint pain up to 12% at different follow-up points. Muscle and joint pain that persists for a year after a viral infection is the pattern the fascial model attributes to tissue that never regained its supply.
Study notesHeterogeneous studies.
2025Meta-analysisMusculoskeletal manifestations in post-acute sequelae of SARS-CoV-2 infection: a systematic review and meta-analysisFrontiers in Public Health. Verma A et al.
Who and what was studied64 observational studies of musculoskeletal symptoms after COVID-19.
What it foundPooled prevalence of muscle pain was 28%, still 25.9% at 12 months after infection, with joint pain in 14.8% and muscle weakness in 12.9%. Muscle pain, the symptom that lives in the myofascial tissue, is the most common musculoskeletal outcome of the infection.
Study notesHigh heterogeneity.
2022Case seriesMyofascial pain syndrome and SARS-CoV-2: a case seriesPain Management. Patel J et al.
Who and what was studiedChart review of patients at a pain clinic who developed or worsened myofascial pain syndrome after COVID-19.
What it foundPatients developed new or worsening myofascial pain, specifically trigger points, after the infection. The authors propose a relationship between COVID-19 and myofascial pain syndrome, which they describe as chronic muscle pain affecting the connective tissue in the muscles.
Study notesSmall case series.
ME/CFS2 studies
Recent tissue studies show that ME/CFS involves structural changes in peripheral tissue that inactivity alone cannot explain, moving the condition from a purely central explanation toward one that includes the tissue.
2025ReviewKey pathophysiological role of skeletal muscle disturbance in post-COVID and ME/CFS: accumulated evidenceJournal of Cachexia, Sarcopenia and Muscle. Scheibenbogen C, Wirth KJ.
Who and what was studiedReview of tissue-level evidence in ME/CFS and post-COVID ME/CFS.
What it foundReports strong recent evidence for a key role of muscle-tissue pathology in ME/CFS, including electron microscopy showing structural damage in muscle, and explains the condition through hypoperfusion and ischaemia of peripheral tissue rather than a purely central process. Hypoperfusion and ischaemia of peripheral tissue is the same shortfall in supply that leaves fascia without the water and nutrients it needs.
Study notesNarrative review.
2026Imaging studySkeletal muscle properties in long COVID and ME/CFS differ from those induced by bed restNature Communications. Charlton BT et al.
Who and what was studiedLong COVID and ME/CFS patients compared with healthy people before and after 60 days of strict bed rest, and with matched controls; exercise testing and muscle biopsies.
What it foundTissue changes in ME/CFS and long COVID patients were different from those caused by inactivity alone, so deconditioning cannot explain them. Both patient groups had more glycolytic fibres and ME/CFS patients showed a specific fibre atrophy. The tissue itself is altered. Muscle biopsies include the fascia that wraps and threads through the muscle; structural change in the tissue that inactivity cannot explain is what a persistent tissue-level problem looks like.
Study notesBed-rest comparison study.
Multiple sclerosis1 study
Half of people with relapsing-remitting MS have myofascial pain syndrome, and treating the myofascial tissue directly reduced their pain and fatigue.
2020Clinical trialPrevalence and impact of myofascial pain syndrome in relapsing-remitting multiple sclerosis and the effects of local anesthetic injectionsMultiple Sclerosis and Related Disorders. Tutuncu M et al.
Who and what was studied137 patients with relapsing-remitting MS screened for myofascial pain syndrome; 25 treated with trigger point injections and followed.
What it foundMyofascial pain syndrome was present in 51.9% of MS patients. Treating the myofascial tissue directly with anaesthetic injections produced a significant fall in pain and fatigue and a rise in quality of life scores at three months (p<0.001).
Study notesOpen-label treatment arm.
Post-stroke stiffness2 studies
The hyaluronan model of stiffness has its clearest human evidence here. Imaging shows more hyaluronan in stiff muscle after stroke, and breaking it down with an enzyme restores movement.
2019Imaging studyQuantifying muscle glycosaminoglycan levels in patients with post-stroke muscle stiffness using T1ρ MRIScientific Reports. Menon RG et al.
Who and what was studied5 patients with post-stroke muscle stiffness and 5 healthy controls; T1ρ MRI mapping of hyaluronan content in the upper arm before and after hyaluronidase injections.
What it foundHyaluronan content was significantly higher in the stiff biceps of patients than controls (34.04 vs 26.70 ms, p = 0.006) and fell after the enzyme that breaks down hyaluronan was injected. The authors describe this as imaging corroboration of the hyaluronan hypothesis of muscle stiffness. Direct imaging evidence in humans that hyaluronan builds up in stiff tissue and that clearing it restores movement, the core claim of the densification model.
Study notesSmall pilot study.
- 2016Human recombinant hyaluronidase injections for upper limb muscle stiffness in individuals with cerebral injuryEBioMedicine. Raghavan P, Lu Y, Mirchandani M, Stecco A.
Menopause6 studies
More than 70% of women develop musculoskeletal pain and stiffness through menopause. Fascia responds directly to female hormones: its cells carry estrogen and relaxin receptors, expressed less after menopause, and connective tissue collagen falls with estrogen, which is the physical basis for why stiffness so often arrives with hormonal transitions.
2024ReviewThe musculoskeletal syndrome of menopauseClimacteric. Wright VJ et al.
Who and what was studiedReview introducing the term for the collective musculoskeletal effects of losing estrogen.
What it foundMore than 70% of women experience musculoskeletal symptoms through the menopause transition and 25% are disabled by them, including joint pain and stiffness, largely driven by estrogen loss. The authors introduce the term musculoskeletal syndrome of menopause because the pattern goes unrecognised. Estrogen loss changes connective tissue collagen and fascial cells carry estrogen receptors; the syndrome this paper names is what that looks like in a woman's body.
Study notesNarrative review.
2012ReviewThe effect of menopause on the skin and other connective tissuesGynecological Endocrinology. Calleja-Agius J, Brincat M.
Who and what was studiedReview of estrogen and connective tissue.
What it foundThere is a strong correlation between connective tissue collagen loss and estrogen deficiency at menopause, and estrogen has profound effects on connective tissue turnover no matter the site. Estrogen use after menopause increases collagen content, thickness and elasticity. Fascia is connective tissue, its cells carry estrogen receptors, and collagen loss with estrogen deficiency is measured here across connective tissues; the mechanism for menopausal stiffness runs through the fascia.
Study notesNarrative review.
2018ReviewEffect of estrogen on musculoskeletal performance and injury riskFrontiers in Physiology. Chidi-Ogbolu N, Baar K.
Who and what was studiedReview of estrogen's effects on muscle, tendon and ligament.
What it foundEstrogen has a dramatic effect on musculoskeletal function beyond bone: it increases the collagen content of connective tissues and directly changes the stiffness of tendons and ligaments. Losing it changes the connective tissue. Estrogen builds connective tissue collagen and sets tendon and ligament stiffness; fascia is the same collagen-based tissue and responds to the same hormone.
Study notesNarrative review.
2016ReviewSex hormones and tendonAdvances in Experimental Medicine and Biology. Hansen M, Kjaer M.
Who and what was studiedReview of sex hormone effects on tendon and ligament collagen.
What it foundEstrogen enhances tendon collagen synthesis and affects fibre cross-linking and joint laxity, and very low estrogen levels are less favourable for connective tissue under load or in recovery. The connective tissue's ability to maintain itself depends on the hormone that falls at menopause. The same collagen synthesis that keeps tendon healthy keeps fascia healthy, and both depend on estrogen.
Study notesNarrative review.
- 2016Hormone receptor expression in human fascial tissueEuropean Journal of Histochemistry. Fede C et al.
- 2019Sensitivity of the fasciae to sex hormone levels: modulation of collagen-I, collagen-III and fibrillin productionPLOS ONE. Fede C et al.
Post-surgical pain1 study
Fascia is one of the more densely innervated soft tissues around a joint, which researchers propose as a reason pain can persist after otherwise successful surgery.
- 2020Fascia and soft tissues innervation in the human hip and their possible role in post-surgical painJournal of Orthopaedic Research. Fede C et al.
Where the research is heading
Alongside the conditions above, a growing number of researchers are proposing fascial densification as a shared mechanism behind many other chronic pain and stiffness conditions. The theories build on the same anatomy, innervation and imaging findings listed in Part A. Direct measurements of fascia in each of these conditions are the work now under way, and this page will be updated as they publish.
Part B
Lissom™
Lissom™ is a nine-ingredient formula built around the mechanism above. This part explains how the formula is organised, then lists the published research on each ingredient, with the same evidence labels as Part A.
How the formula is built
Healthy fascia is soft and supple because it has a steady supply of water and nutrients. When that supply falls short, fascia dehydrates, densifies and compresses the muscles and nerves running through it. Lissom™ was built backwards from that mechanism. Every ingredient has one of four jobs, and the research below is what has been published on each one's effect on connective tissue hydration, collagen, soft-tissue swelling, inflammation, and pain and stiffness.
Rehydrate the fascia
Give the fascia back the hyaluronic acid and other nutrients it needs to hold water. High-molecular-weight hyaluronic acid, with pine bark extract, which raises the body's own hyaluronic acid production.
Feed the fascia's structure
Fascia holds water inside a framework of collagen and proteoglycans. Silica, manganese, boron, grape seed extract and gotu kola supply what that framework is built and maintained from.
Release densified tissue
Break down the protein buildup that keeps densified fascia compressed. Serrapeptase, a proteolytic enzyme with trial evidence for reducing soft-tissue swelling.
Calm the inflammation that keeps it tight
Low-grade inflammation thickens the fluid between fascial layers and sensitises the nerve endings inside them. Boswellia, boron, grape seed extract and gotu kola carry the inflammatory-marker and pain-and-stiffness evidence.
Ingredient table
One row per ingredient: what it does in the formula, what the published research found, and what kind of evidence it is. The count links to the studies.
| Ingredient | What it does in the formula | What the research found | Type of evidence | Studies |
|---|---|---|---|---|
| Hyaluronic acid | Rehydrates the fascia | Less pain and stiffness in 9 of 11 trials reviewed; better knee comfort in adults without arthritis; more water held in connective tissue | Systematic review and randomised trials | 8 |
| Pine bark extract | Rehydrates the fascia and calms inflammation | 56% drop in joint symptom scores and tripled walking distance in a placebo-controlled trial; lower CRP; more of the body's own hyaluronic acid synthase | Randomised trials | 4 |
| Grape seed extract | Feeds the fascia's structure and calms inflammation | Lower hs-CRP across pooled trials; less fluid retention and swelling; collagen and elastin protection | Meta-analyses and randomised trials | 4 |
| Bamboo extract (silica) | Feeds the fascia's structure | Firmer, better-hydrated connective tissue in placebo-controlled trials of bioavailable silicon; silicon is needed for the cross-links that hold collagen and proteoglycans together | Randomised trials and reviews | 5 |
| Manganese | Feeds the fascia's structure | Required for the enzymes that build proteoglycans and recycle collagen; part of two placebo-controlled knee trials | Mechanistic studies and combination trials | 4 |
| Boron | Calms inflammation | Less knee discomfort within 14 days in a placebo-controlled trial; lower hs-CRP and TNF-α | Randomised trials | 4 |
| Serrapeptase | Releases densified tissue | Less soft-tissue swelling and stiffness after surgery in a randomised trial; faster reduction in swelling than paracetamol after injury | Randomised and comparative trials | 4 |
| Boswellia serrata | Calms inflammation | Significantly less pain and stiffness across pooled trials; improvement within five days; lower TNF-α, hs-CRP and IL-6 | Two meta-analyses and several randomised trials | 6 |
| Gotu kola (Centella asiatica) | Feeds the fascia's structure and calms inflammation | Stimulates collagen I production; lower IL-1β, IL-6 and TNF-α; less swelling and capillary leakage in placebo-controlled trials | Systematic review and randomised trials | 6 |
Ingredient research45 studies
Hyaluronic acid8 studies
RoleRehydrates the fascia
2024Systematic reviewOral hyaluronic acid in osteoarthritis and low back pain: a systematic reviewMediterranean Journal of Rheumatology. de Carvalho JF, Davidson J.
Who and what was studied11 articles (597 patients) on oral hyaluronic acid in rheumatic conditions, 1966–May 2024; 10 in osteoarthritis and 1 in low back pain, follow-up 4 weeks to 12 months.
What it foundNine of the eleven studies reported improvement in outcomes such as pain, WOMAC, joint function, Lequesne index and stiffness. Two studies measured cytokines and found them reduced after oral hyaluronic acid. Adverse effects were rare and mild. Hyaluronic acid is what keeps the fluid between fascial layers thin and mobile; oral hyaluronic acid is the direct way to give it back.
Study notesQualitative synthesis; no pooled effect size. Included trials used several branded products.
2024Randomized controlled trialOral sodium hyaluronate relieves knee discomfort: a 12-week double-blinded, placebo-controlled studyExperimental and Therapeutic Medicine. Sugiyama K et al.
Who and what was studiedHealthy adults around age 60 with knee discomfort but no diagnosed osteoarthritis (Kellgren-Lawrence grade ≤1); 12 weeks; visual analogue scales, mobility and leg-strength tests.
What it foundStudied whether oral hyaluronan helps knees before osteoarthritis has developed, in contrast to earlier trials that enrolled diagnosed patients. Total visual analogue scores for pain, stiffness and discomfort were significantly suppressed in the hyaluronate group compared with placebo over 12 weeks. Mobility tests and blood markers did not differ between groups. Benefit in people without joint damage points to an effect on the connective tissue around the joint, where fascia sits, rather than on cartilage.
Study notesAuthored by researchers at a hyaluronic acid producer.
2020Randomized controlled trialShort-term effect of a new oral sodium hyaluronate formulation on knee osteoarthritis: a double-blind, randomized, placebo-controlled clinical trialDiseases. Cicero AFG et al.
Who and what was studied60 adults with symptomatic knee osteoarthritis; 8 weeks; WOMAC, Lequesne index, pain VAS, rescue medication use and range of motion.
What it foundPain, total WOMAC, Lequesne index and range of motion improved significantly from baseline in the hyaluronate group, and at 60 days pain VAS and WOMAC pain were significantly lower than placebo (p<0.05). Weekly use of rescue medication also fell. Pain and movement improved within eight weeks, faster than cartilage can change, which points to the connective tissue around the joint.
Study notesPilot study.
2025Animal or lab studyRole of oral hyaluronic acid for joint health: insights from rat models and clinical trialsFrontiers in Nutrition. Wang B et al.
Who and what was studiedRat osteoarthritis model comparing hyaluronic acid of different molecular weights, followed by a human clinical trial of the selected form.
What it foundIn rats, oral hyaluronic acid reduced joint swelling, raised hyaluronic acid levels in serum and synovial fluid, and lowered pro-inflammatory cytokines, MMPs, iNOS and COX-2, most strongly with high-molecular-weight forms. In the human trial it significantly reduced WOMAC pain, stiffness and function scores with no significant impact on blood or urine safety markers. Oral hyaluronic acid raised hyaluronic acid levels in the tissue and lowered the inflammatory signals that thicken the fluid between fascial layers.
Study notesAuthored by researchers at a hyaluronic acid producer; the human arm is a pilot trial.
2016ReviewOral hyaluronan relieves knee pain: a reviewNutrition Journal. Oe M et al.
Who and what was studiedReview of randomised, double-blind, placebo-controlled trials of oral hyaluronan for knee pain, 2008–2015, plus mechanism and safety.
What it foundConcludes that the trials support oral hyaluronan for symptoms associated with synovitis, particularly knee pain, relief of effusion or inflammation, and muscular knee strength. Describes the proposed mechanism of receptor binding in the intestinal epithelium. The review covers how ingested hyaluronan is absorbed and acts, the mechanism by which oral hyaluronic acid can reach connective tissue such as fascia.
Study notesReview authored by researchers at a hyaluronic acid producer.
2015Randomized controlled trialIngestion of hyaluronans (molecular weights 800k and 300k) improves dry skin conditions: a randomized, double blind, controlled studyJournal of Clinical Biochemistry and Nutrition. Kawada C et al.
Who and what was studied61 subjects with dry skin; oral hyaluronan of two molecular weights or placebo for 6 weeks; skin moisture content measured.
What it foundSkin moisture content increased more in both hyaluronan groups than in placebo during ingestion, and the 300k group still showed significantly better moisture two weeks after stopping. Dermatologist evaluation found no adverse events. Used here as evidence that ingested hyaluronan can raise water content in a connective tissue. Skin is connective tissue continuous with the superficial fascia; ingested hyaluronan put water back into a connective tissue and kept it there.
Study notesSkin, not fascia, was measured.
2014ReviewIngested hyaluronan moisturizes dry skinNutrition Journal. Kawada C et al.
Who and what was studiedReview of absorption, distribution and pharmacological action of ingested hyaluronan.
What it foundSummarises evidence that ingested hyaluronan is absorbed and distributed in part to the skin, contributes to increased synthesis of hyaluronan, and promotes fibroblast proliferation, and that in a randomised placebo-controlled study it increased skin moisture in people with dry skin. Distribution to skin and increased hyaluronan synthesis in fibroblasts is the pathway by which oral hyaluronic acid reaches and rehydrates connective tissue, including fascia.
Study notesReview; distribution evidence is partly from animal work.
2022Meta-analysisEffectiveness of dietary supplement for skin moisturizing in healthy adults: a systematic review and meta-analysis of randomized controlled trialsFrontiers in Nutrition. Sun Q et al.
Who and what was studied66 randomised controlled trials of oral supplements for skin moisturising, 2000–2021; meta-analysis for supplements with four or more trials.
What it foundA statistically significant positive effect on skin hydration was found for both hyaluronan and procyanidin (the proanthocyanidin class found in pine bark and grape seed), with insufficient trials to judge water loss. Hyaluronan and proanthocyanidins, two of the rehydrating ingredients in Lissom™, both measurably raise water content in connective tissue.
Study notesSkin hydration as a proxy for connective tissue hydration.
Pine bark extract4 studies
RoleRehydrates the fascia and calms inflammation
2008Randomized controlled trialTreatment of osteoarthritis with Pycnogenol: the SVOS (San Valentino Osteo-arthrosis Study)Phytotherapy Research. Belcaro G et al.
Who and what was studied156 osteoarthritis patients (77 pine bark extract, 79 placebo) for 3 months; WOMAC, treadmill walking distance, medication use and foot oedema.
What it foundGlobal WOMAC score fell 56% with pine bark extract versus 9.6% with placebo (p<0.05). Treadmill walking distance rose from 68 m to 198 m versus 65 m to 88 m on placebo. Use of pain medication fell 58%, and foot oedema improved in 79% of treated patients versus 1% of controls. The oedema that resolved in four out of five patients is fluid held in the connective tissue around the joint; pine bark acted on the tissue, not the bone.
Study notesTrial sponsored by the extract's manufacturer.
2008Randomized controlled trialEffect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritisPhytotherapy Research. Cisár P et al.
Who and what was studied100 patients with stage I–II knee osteoarthritis; pine bark extract or placebo for 3 months; WOMAC every two weeks and weekly pain VAS.
What it foundWOMAC improved (p<0.05) and pain fell (p<0.04) in the pine bark group with no effect from placebo. Analgesic use decreased on pine bark and increased on placebo. Improvement in mild osteoarthritis, before major joint damage, points to the connective tissue around the joint where fascia sits.
Study notesSponsored by the extract's manufacturer.
2008Randomized controlled trialVariations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with PycnogenolRedox Report. Belcaro G et al.
Who and what was studiedSubset of the SVOS trial with elevated C-reactive protein at baseline: 29 on pine bark extract and 26 on placebo, 3 months.
What it foundPlasma CRP fell from 3.9 mg/L to 1.1 mg/L in the pine bark group versus 3.9 to 3.6 mg/L on placebo (p<0.05 between groups). Plasma free radicals fell to 70.1% of baseline and fibrinogen to 62.8% of baseline. CRP is the systemic marker of the low-grade inflammation that keeps fascia tight; pine bark reduced it by more than two-thirds.
Study notesSubgroup analysis of the SVOS trial.
2012Clinical trialPycnogenol effects on skin elasticity and hydration coincide with increased gene expressions of collagen type I and hyaluronic acid synthase in womenSkin Pharmacology and Physiology. Marini A et al.
Who and what was studied20 healthy postmenopausal women supplemented for 12 weeks; skin measured by corneometry, cutometry and ultrasound, with biopsies for gene expression.
What it foundHydration and elasticity of skin improved significantly, most in women with dry skin at baseline. This was accompanied by a significant increase in mRNA expression of hyaluronic acid synthase-1, the enzyme the body uses to make its own hyaluronic acid, and of collagen type I genes. This is the study behind including pine bark for hydration rather than only for inflammation. Hyaluronic acid synthase-1 is the enzyme fascia's own cells use to make the hyaluronic acid that keeps its layers hydrated; pine bark turned it up.
Study notesOpen-label study in 20 women.
Grape seed extract4 studies
RoleFeeds the fascia's structure and calms inflammation
2021Meta-analysisThe effect of grape seed extract supplementation on oxidative stress and inflammation: a systematic review and meta-analysis of controlled trialsInternational Journal of Clinical Practice. Foshati S et al.
Who and what was studied23 studies in the review, 19 in the meta-analysis, covering biomarkers of oxidative stress and inflammation.
What it foundGrape seed extract significantly decreased malondialdehyde (SMD −1.04), oxidised LDL (SMD −0.44) and high-sensitivity C-reactive protein (WMD −0.48 mg/L, 95% CI −0.94 to −0.03). Low-grade inflammation, measured as hs-CRP, is what keeps hyaluronan clumped and fascia densified; grape seed extract lowered it.
Study notesTrial populations were mostly cardiometabolic.
2021Meta-analysisThe effect of grape products containing polyphenols on C-reactive protein levels: a systematic review and meta-analysis of randomised controlled trialsBritish Journal of Nutrition. Sarkhosh-Khorasani S, Hosseinzadeh M.
Who and what was studied17 randomised trials, 668 participants, of grape products including grape seed extract.
What it foundGrape polyphenols decreased CRP significantly overall (SMD −0.229, p = 0.013), with larger effects at higher doses, in trials of 12 weeks or more, and in people with a clinical condition; grape seed extract was among the products showing a significant effect. Less systemic inflammation means less of the signal that thickens the fluid between fascial layers.
Study notesPools several grape products, not grape seed alone.
2013Randomized controlled trialProanthocyanidin-rich grape seed extract reduces leg swelling in healthy women during prolonged sittingJournal of the Science of Food and Agriculture. Sano A et al.
Who and what was studiedHealthy Japanese women in double-blind, placebo-controlled crossover trials of single intake and 14-day intake, followed by 6 hours of sitting.
What it foundLeg volume distension, increase in body extracellular fluid, and leg water were all significantly suppressed in the grape seed extract groups compared with placebo. Leg swelling is fluid retained in the superficial fascia and connective tissue; grape seed extract kept it out.
Study notesHealthy women; measures fluid retention rather than pain.
2025ReviewBeneficial effects of proanthocyanidins on skin aging: a reviewFrontiers in Nutrition. Ye H et al.
Who and what was studiedNarrative review of proanthocyanidins (the polyphenol class in grape seed and pine bark).
What it foundReviews evidence that proanthocyanidins reduce oxidative stress, promote collagen and elastin synthesis, and dampen inflammatory signalling in aged skin, while noting low bioavailability and environmental instability as limits. Collagen and elastin are the framework fascia holds its water in; proanthocyanidins protect and promote both.
Study notesMostly cell and animal data.
Bamboo extract (silica)5 studies
RoleFeeds the fascia's structure
2005Randomized controlled trialEffect of oral intake of choline-stabilized orthosilicic acid on skin, nails and hair in women with photodamaged skinArchives of Dermatological Research. Barel A et al.
Who and what was studied50 women with photodamaged facial skin randomised to a bioavailable silicon supplement or placebo for 20 weeks; skin microrelief, hydration and mechanical properties measured.
What it foundSerum silicon rose in the supplemented group. Skin roughness parameters worsened in the placebo group (+6 to +11%) but improved in the silicon group (−8 to −19%), a significant difference, and mechanical anisotropy improved. Silicon was suggested to have a function in forming and maintaining connective tissue. Skin firmness and roughness reflect the state of its collagen framework, and skin is continuous with the superficial fascia; bioavailable silicon improved it against placebo.
Study notesUses orthosilicic acid, a different silicon source from bamboo silica; skin measured, not fascia.
2018Randomized controlled trialEvaluation of cutaneous rejuvenation associated with the use of ortho-silicic acid stabilized by hydrolyzed marine collagenJournal of Cosmetic Dermatology. Petersen Vitello Kalil CL et al.
Who and what was studied22 patients randomised to a stabilised orthosilicic acid supplement or placebo for 90 days.
What it foundClinical evaluation showed changes in skin texture, firmness and hydration that were statistically superior in the silicon group, with 80% treatment satisfaction and no side effects. Firmer, better-hydrated skin means a better-maintained connective tissue framework, which is what silicon is in the formula to support.
Study notesSmall trial; silicon was combined with collagen.
2021ReviewSilicon: a neglected micronutrient essential for bone healthExperimental Biology and Medicine. Rondanelli M et al.
Who and what was studiedNarrative review of 8 human studies (over 10,000 subjects) on silicon intake or supplementation.
What it foundReports that in vitro and animal studies show silicon is linked to glycosaminoglycans and plays an important role in forming cross-links between collagen and proteoglycans, which is the mechanistic reason it appears in a connective tissue formula. Human evidence relates to bone density. The cross-links between collagen and proteoglycans that silicon supports are what let fascia hold water inside its framework.
Study notesBone-focused; connective tissue mechanism from lab and animal data.
2024Systematic reviewSilicon supplementation for bone health: an umbrella review attempting to translate from animals to humansNutrients. Pritchard A, Nielsen BD.
Who and what was studiedUmbrella review of controlled animal studies of silicon and bone.
What it foundSummarises the levels of silicon intake that affect bone and mineral metabolism across species, and the association between silicon and the organic (collagen) matrix of bone and connective tissue. Silicon tracks with the collagen matrix of connective tissue, the framework that fascia is built from.
Study notesAnimal data; scope is bone.
2007ReviewSilicon and bone healthJournal of Nutrition, Health and Aging. Jugdaohsingh R.
Who and what was studiedReview of silicon metabolism and its role in bone and connective tissue.
What it foundStates that accumulating evidence over 30 years strongly suggests dietary silicon is beneficial to bone and connective tissue health, with proposed mechanisms including synthesis and stabilisation of collagen. Collagen synthesis and stabilisation is the job silicon does in every connective tissue, fascia included.
Study notesReview; mechanisms described as not yet clear.
Manganese4 studies
RoleFeeds the fascia's structure
2006Animal or lab studyHuman recombinant prolidase from eukaryotic and prokaryotic sources: expression, purification, characterization and long-term stabilityFEBS Journal. Lupi A et al.
Who and what was studiedBiochemical characterisation of recombinant human prolidase.
What it foundProlidase, the enzyme that recycles proline and hydroxyproline from collagen breakdown for new collagen synthesis, is manganese-dependent. Manganese together with glutathione improved the enzyme's activity and stability. Lack of prolidase activity in humans causes severe skin lesions among other problems. Fascia's collagen is constantly recycled, and prolidase is the enzyme that recovers the building blocks; without manganese it does not work.
Study notesEnzyme biochemistry; prolidase is the enzyme that recycles collagen's proline.
1994Animal or lab studyInfluence of manganese deficiency on the characteristics of proteoglycans of avian epiphyseal growth plate cartilagePoultry Science. Liu AC, Heinrichs BS, Leach RM Jr.
Who and what was studiedProteoglycans extracted from growth-plate cartilage of manganese-deficient and normal chicks.
What it foundManganese deficiency reduced the total amount of cartilage proteoglycans, and a quarter of the remaining proteoglycan monomers were abnormal with reduced carbohydrate content. The authors attribute manganese's role in skeletal development to its part in proteoglycan biosynthesis. Proteoglycans are the water-binding molecules of connective tissue, including fascia; without manganese the body makes fewer of them and makes them wrong.
Study notesAnimal study.
2000Randomized controlled trialEfficacy of a combination of glucosamine hydrochloride, low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritisOsteoarthritis and Cartilage. Das A Jr, Hammad TA.
Who and what was studied93 knee osteoarthritis patients randomised to a glucosamine, chondroitin and manganese ascorbate combination or placebo for 6 months.
What it foundPatients with radiographically mild or moderate osteoarthritis showed significant improvement in the Lequesne index at 4 and 6 months (p = 0.003 and p = 0.04), with a 52% response rate versus 28% on placebo. Patients with severe disease did not improve significantly. Manganese was in the formula for the same reason it is in this one: it is required for building the proteoglycans and collagen of connective tissue.
Study notesCombination product, so manganese's own contribution cannot be separated out.
1999Randomized controlled trialGlucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot studyMilitary Medicine. Leffler CT et al.
Who and what was studied34 US Navy men with chronic pain and radiographic degenerative joint disease of the knee or low back; 16-week crossover trial.
What it foundKnee osteoarthritis symptoms were relieved on the combination: summary disease score −16.3% (p = 0.05), pain VAS at clinic visits −26.6% (p = 0.05), physical examination score −43.3% (p = 0.01). A benefit for the spine was neither shown nor excluded. Knee pain improved with a combination that included manganese as a cofactor for connective tissue synthesis.
Study notesCombination product; small pilot.
Boron4 studies
RoleCalms inflammation
2014Randomized controlled trialShort-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical studyClinical Interventions in Aging. Pietrzkowski Z et al.
Who and what was studied60 participants with self-reported knee discomfort randomised to calcium fructoborate (a plant-form boron complex) or placebo; WOMAC and McGill Pain Questionnaire at 7 and 14 days.
What it foundEstimated treatment differences versus placebo on the McGill Pain Questionnaire were −5.8 (p = 0.0009) at day 7 and −8.9 (p<0.0001) at day 14, and on WOMAC −5.3 (p = 0.06) at day 7 and −13.73 (p<0.0001) at day 14. The placebo group did not change. Knee discomfort relieved within two weeks, faster than joint structure changes, points to the inflamed connective tissue around the joint.
Study notesTwo-week trial sponsored by the ingredient's manufacturer.
2011Randomized controlled trialA double-blind, placebo-controlled pilot study to evaluate the effect of calcium fructoborate on systemic inflammation and dyslipidemia markers for middle-aged people with primary osteoarthritisBiological Trace Element Research. Scorei R et al.
Who and what was studied60 completers with knee osteoarthritis in a 15-day placebo-controlled trial; CRP, fibrinogen, ESR and lipids measured.
What it foundCalcium fructoborate showed a beneficial effect on inflammatory markers in all treated groups compared with placebo, with slight changes in lipid metabolism and no serious adverse events. CRP and fibrinogen are markers of the low-grade inflammation that keeps fascia tight; boron reduced them within two weeks.
Study notesTwo-week pilot study.
2011Human experimental studyComparative effects of daily and weekly boron supplementation on plasma steroid hormones and proinflammatory cytokinesJournal of Trace Elements in Medicine and Biology. Naghii MR et al.
Who and what was studied8 healthy men; blood sampled over 6 hours after a single boron dose and again after one week of daily supplementation.
What it foundPlasma boron rose quickly after ingestion. Six hours after supplementation there was a significant decrease in high-sensitivity CRP and TNF-α, with further hormone changes after a week. hs-CRP and TNF-α are the inflammatory signals that thicken the fluid between fascial layers; boron lowered both within hours.
Study notesn = 8; short duration.
2015ReviewNothing boring about boronIntegrative Medicine: A Clinician's Journal. Pizzorno L.
Who and what was studiedNarrative review.
What it foundSummarises human evidence that boron is important for bone growth and maintenance, wound healing, the body's use of estrogen, testosterone, vitamin D and magnesium, and reduction of inflammatory markers including hs-CRP and TNF-α, and that it raises antioxidant enzymes. Boron's effects on wound healing, inflammatory markers and connective tissue are the reasons it sits in the framework-and-inflammation half of the formula.
Study notesNarrative review.
Serrapeptase4 studies
RoleReleases densified tissue
2021Randomized controlled trialEfficacy of serratiopeptidase after impacted third molar surgery: a randomized controlled clinical trialBMC Oral Health. Tamimi Z et al.
Who and what was studied133 patients after surgical removal of an impacted lower third molar, randomised to serratiopeptidase plus paracetamol or placebo plus paracetamol for 5 days; pain, trismus and swelling measured to day 5.
What it foundSerratiopeptidase significantly improved trismus on day 4 (27.30 ± 7.3 mm versus 32.06 ± 7.7 mm, p<0.001) and reduced swelling (earlobe-to-chin distance 111.49 ± 8.1 mm versus 115.39 ± 9.9 mm, p<0.001). Reported pain did not differ significantly between groups. Post-surgical swelling and stiffness are the result of fluid and protein debris accumulating in soft connective tissue; serrapeptase cleared it faster.
Study notesMeasures acute post-surgical swelling over five days.
2024Clinical trialEfficacy and safety of serrapeptase on ankle sprain cases: a single center prospective comparative studyJournal of Clinical Orthopaedics and Trauma. Stamati A et al.
Who and what was studied76 patients aged 18–53 with grade II ankle sprain, assigned to serrapeptase or paracetamol for 10 days; oedema measured by two methods and pain by VAS.
What it foundSerrapeptase produced a superior reduction in ankle joint oedema on day 3 and day 10 compared with paracetamol, while pain did not differ significantly between the groups. The oedema after an ankle sprain sits in the fascia and connective tissue around the joint; serrapeptase reduced it faster than a standard painkiller.
Study notesNot randomised; compared against paracetamol.
2022ReviewSerratiopeptidase: an integrated view of multifaceted therapeutic enzymeBiomolecules. Nair SR, C SD.
Who and what was studiedReview of the enzyme's properties, therapeutic uses, production and analysis.
What it foundDescribes serratiopeptidase as a widely used anti-inflammatory enzyme, an alternative to NSAIDs, with established use for post-operative swelling and proposed uses in arthritis and other conditions. A proteolytic enzyme that breaks down inflammatory protein and fibrin debris, the buildup that keeps densified tissue compressed.
Study notesNarrative review.
2017ReviewThe role of serratiopeptidase in the resolution of inflammationAsian Journal of Pharmaceutical Sciences. Tiwari M.
Who and what was studiedNarrative review.
What it foundDescribes serratiopeptidase as a proteolytic enzyme with anti-inflammatory, anti-oedemic and fibrinolytic activity and affinity for cyclooxygenase enzymes, while noting a lack of research evidence and available literature compared with conventional drugs. Anti-oedemic and fibrinolytic activity is exactly the action needed on densified, swollen connective tissue.
Study notesNarrative review.
Boswellia serrata6 studies
RoleCalms inflammation
2020Meta-analysisEffectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysisBMC Complementary Medicine and Therapies. Yu G et al.
Who and what was studied7 randomised trials, 545 patients with osteoarthritis; Boswellia or its extract versus placebo or conventional medicine.
What it foundCompared with control, Boswellia reduced pain (VAS WMD −8.33; WOMAC pain WMD −14.22, p = 0.0006) and stiffness (WOMAC stiffness WMD −10.04, p = 0.0007) and improved function (WOMAC function WMD −10.75; Lequesne index WMD −2.27, both p<0.00001). The authors recommend a treatment duration of at least four weeks. Stiffness is a fascial symptom; Boswellia's pooled effect on stiffness is as clear as its effect on pain.
Study notesHigh heterogeneity across trials; few trials.
2024Meta-analysisEfficacy of extracts of oleogum resin of Boswellia in the treatment of knee osteoarthritis: a systematic review and meta-analysisPhytotherapy Research. Dalmonte T et al.
Who and what was studied13 randomised controlled studies in knee osteoarthritis (850 patients with WOMAC data, 1185 with VAS data).
What it foundThe largest pooled analysis of Boswellia for knee osteoarthritis. Against placebo, Boswellia extracts produced significantly lower WOMAC scores, a result confirmed by meta-regression. The authors note this matters for people who cannot tolerate NSAIDs and call for further high-quality trials. Boswellia calms the inflammation that thickens the fluid between fascial layers and sensitises the nerve endings inside them.
Study notesThe pooled result across all comparators (not only placebo) was limited by heterogeneity between trials.
2024Randomized controlled trialA standardized Boswellia serrata extract shows improvements in knee osteoarthritis within five days: a double-blind, randomized, three-arm, multi-center, placebo-controlled trialFrontiers in Pharmacology. Majeed A et al.
Who and what was studied105 newly diagnosed knee osteoarthritis patients randomised to placebo or two doses of an AKBA-standardised extract for 90 days; VAS, WOMAC, Lequesne index, 6-minute walk and inflammatory markers (TNF-α, hs-CRP, IL-6) at days 0, 5, 30, 60 and 90.
What it foundPain scores improved from day 5. By day 90, VAS pain fell 45.3% and 61.9% and WOMAC total improved 68.5% and 73.6% at the two doses, with WOMAC stiffness improving 65.6% and 68.9%. Serum TNF-α, hs-CRP and IL-6 decreased in supplemented participants, and no significant adverse events were recorded. The inflammatory markers that fell, TNF-α, IL-6 and hs-CRP, are the same signals that drive hyaluronan to clump and fascia to densify.
Study notesSponsored by the extract's manufacturer.
2008Randomized controlled trialA double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the kneeArthritis Research & Therapy. Sengupta K et al.
Who and what was studied75 knee osteoarthritis patients randomised to two doses of an AKBA-enriched extract or placebo for 90 days; pain and function assessed at days 7, 30, 60 and 90, plus MMP-3 in synovial fluid.
What it foundBoth doses produced clinically and statistically significant improvements in pain and physical function by the end of the study, with benefits reported as early as day 7 at the higher dose, and a reduction in the cartilage-degrading enzyme MMP-3 in synovial fluid. MMP-3 is one of the enzymes that degrades the connective tissue matrix; reducing it protects the framework fascia holds water in.
Study notesSponsored by the extract's manufacturer.
2011Randomized controlled trialA double blind, randomized, placebo controlled clinical study evaluates the early efficacy of Aflapin in subjects with osteoarthritis of kneeInternational Journal of Medical Sciences. Vishal AA, Mishra A, Raychaudhuri SP.
Who and what was studied60 knee osteoarthritis patients randomised to a Boswellia-derived composition or placebo for 30 days; assessed at days 5, 15 and 30.
What it foundClinically and statistically significant improvements in pain and physical function scores, with significant improvement reported as early as five days. Relief within five days is faster than structural joint change, pointing to an effect on inflammation in the soft connective tissue around the joint.
Study notesSponsored by the extract's manufacturer; 30-day trial.
2003Randomized controlled trialEfficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee: a randomized double blind placebo controlled trialPhytomedicine. Kimmatkar N et al.
Who and what was studied30 knee osteoarthritis patients in a crossover design, 8 weeks per phase.
What it foundAll patients on the extract reported decreased knee pain, increased knee flexion and increased walking distance, and swelling became less frequent. Differences from placebo were statistically significant and, the authors say, clinically relevant. X-rays did not change. Less swelling and more movement in the joint with no change on X-ray points to the soft connective tissue around the joint, not the bone.
Study notesSmall early trial.
Gotu kola (Centella asiatica)6 studies
RoleFeeds the fascia's structure and calms inflammation
2022Systematic reviewA systematic review of the effect of Centella asiatica on wound healingInternational Journal of Environmental Research and Public Health. Arribas-López E et al.
Who and what was studiedFour clinical trials of Centella asiatica in wound healing, reviewed under PRISMA.
What it foundConcludes Centella asiatica might enhance wound healing through improved angiogenesis, driven by its stimulating effect on collagen I, fibroblast growth factor and VEGF, and has an anti-inflammatory effect seen as reductions in IL-1β, IL-6, TNF-α, PGE2 and COX-2. Collagen I production and lower inflammatory cytokines are the two things a densified fascia needs to recover its framework and settle.
Study notesFour trials, mostly topical use.
2001Randomized controlled trialTreatment of edema and increased capillary filtration in venous hypertension with total triterpenic fraction of Centella asiatica: a placebo-controlled, randomized, dose-ranging trialAngiology. De Sanctis MT et al.
Who and what was studied52 patients with venous hypertension randomised to two doses of oral Centella triterpenes or placebo for 4 weeks, plus 10 normal subjects; capillary filtration rate, ankle circumference and ankle oedema measured.
What it foundAfter 4 weeks there was a significant decrease in capillary filtration rate, ankle circumference and ankle oedema in treated patients, greater at the higher dose, with no significant change on placebo. Capillary leakage and oedema are fluid accumulating in the superficial fascia and connective tissue; oral Centella reduced both against placebo.
Study notesOral Centella; venous oedema rather than a pain condition.
2001Randomized controlled trialTotal triterpenic fraction of Centella asiatica in the treatment of venous hypertension: a randomized trial using a combined microcirculatory modelAngiology. Incandela L et al.
Who and what was studiedSingle-blind, placebo-controlled, randomised study of two doses of oral Centella triterpenes in venous hypertensive microangiopathy.
What it foundObjective microcirculation tests (laser Doppler, transcutaneous oxygen and carbon dioxide) were significantly improved by treatment with no change on placebo, and symptom scores improved in parallel, especially at the higher dose. Improved microcirculation means more water and nutrients reaching the tissue, which is the supply fascia depends on.
Study notesOlder trial; single-blind.
2001Randomized controlled trialFlight microangiopathy in medium- to long-distance flights: prevention of edema and microcirculation alterations with total triterpenic fraction of Centella asiaticaAngiology. Cesarone MR et al.
Who and what was studiedPassengers aged 30–50 with mild-moderate venous disease on flights over 3 hours, randomised to oral Centella triterpenes or no treatment.
What it foundAnkle swelling rate and oedema were significantly lower in the treated group (p<0.025), and microcirculation changes with flight time were milder. Swelling in the lower leg is fluid held in the fascia and connective tissue; oral Centella kept it down.
Study notesNo placebo (untreated control).
2023ReviewTherapeutic properties and pharmacological activities of asiaticoside and madecassoside: a reviewJournal of Cellular and Molecular Medicine. Bandopadhyay S et al.
Who and what was studiedReview of the two marker triterpenoid glycosides of Centella asiatica.
What it foundReports wound healing, anti-inflammatory, antioxidant, antifibrotic and anti-arthritic activities of asiaticoside and madecassoside, mostly from preclinical work, alongside their established use in skin and scar conditions. Antifibrotic, anti-inflammatory and collagen-building activity is the combination a stiffened connective tissue needs.
Study notesLittle human data.
2024ReviewTopical application of Centella asiatica in wound healing: recent insights into mechanisms and clinical efficacyPharmaceutics. Witkowska K et al.
Who and what was studiedReview of mechanisms and clinical trials of topical Centella.
What it foundDescribes how asiaticoside, madecassoside, asiatic acid and madecassic acid enhance collagen synthesis, modulate inflammation and offer antioxidant protection. The same compounds that stimulate collagen and calm inflammation in skin act on the connective tissue fascia is made of.
Study notesTopical use only.
Where the research stands
The research on this page is real, and most of it is recent. The anatomy of fascia and its nerve supply are established. Densification has a clear mechanism, a growing body of imaging studies that can measure it, and treatment studies showing that acting on fascia relieves pain. Fascia is now a recognised focus of pain research, with the 2025 scoping review in Part A identifying chronic pain as the field's main direction. Every ingredient in Lissom™ has published research behind the job it does in the formula, from pooled trials for Boswellia and hyaluronic acid to placebo-controlled trials for pine bark, boron, serrapeptase and silicon.
Nearly every study here was published in the last ten years, and the imaging work is mostly from the last five. That is why most people are hearing about fascia for the first time. This page is updated as new studies publish.
All studies cited are independently published, peer-reviewed and publicly verifiable. Lissom did not fund, design or conduct any of the research on this page. Where a study was sponsored by the manufacturer of an ingredient tested, this is noted in the entry. The presence of a study here is not a treatment claim. Lissom™ is a dietary supplement and is not intended to diagnose, treat, cure or prevent any disease.
No studies match. Clear the filters to see everything.